Antibody coupling medicine and application thereof

By designing new antibody-conjugated drugs with high water solubility and optimized connection methods, the shortcomings of existing antibody-conjugated drugs in water solubility and safety are solved, and the efficient targeting and safety of tumor cells is achieved, thus improving the improvement of tumor cells. The therapeutic effect.

CN118924912APending Publication Date: 2024-11-12NOVACYTE THERAPEUTICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410270559.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-03-11
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing antibody-conjugated drugs have shortcomings in water solubility and safety, resulting in toxicity and side effects in some instances, limiting their use in tumor therapy.

Method used

A new compound was designed to improve the water solubility of the drug through specific structural composition, and to reduce damage to normal cells by optimizing the connection of toxin molecules, achieving improved targeting and safety. The compound comprises a structure with hydrophilic groups for coupling to antibodies to form highly effective drug conjugates.

Benefits of technology

It improves the water solubility and safety of the drug, enhances the targeting of tumor cells, reduces the side effects on normal cells, and improves the effectiveness and safety of the treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924912A_ABST
    Figure CN118924912A_ABST
Patent Text Reader

Abstract

The invention relates to an antibody coupling drug and application thereof. Specifically, the invention relates to a compound represented by a formula (I) or an isotope labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, and an application thereof in preparation of a drug for treating or preventing cancers, especially an antibody coupling drug. And P-L-D (I).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Chinese patent application No. 202310519730.1 filed on May 9, 2023, the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present application relates to the field of biomedicine, and in particular to an antibody-drug conjugate and its use. Background Art

[0004] In the past, tumor treatment was mainly based on chemotherapy drugs. Chemotherapy is the preferred systemic cancer treatment method using cytotoxic drugs. It mainly works by interfering with the cell cycle and delaying or completely preventing the reproduction of tumor cells. However, because chemotherapy drugs also indiscriminately kill normal cells, they can cause serious side effects.

[0005] Antibody-Drug Conjugates (ADC) are therapeutic agents formed by coupling antibodies targeting specific antigens and toxin molecules through linkers. They have both the powerful killing effect of traditional small molecule chemotherapy and the tumor targeting of antibody drugs. This also means that compared with traditional chemotherapy drugs, antibody-drug conjugates can accurately bind to tumors and reduce the impact on normal cells (Mullard A, (2013) Nature Reviews Drug Discovery, 12: 329-332; DiJoseph JF, Armellino DC, (2004) Blood, 103: 1807-1814). Therefore, from the perspective of the focused disease areas, the concentration of ADC drugs is very high, mainly concentrated in the field of tumors.

[0006] In 2000, the first antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin, Wyeth Pharmaceuticals Co., Ltd.) was approved for marketing by the US FDA for the treatment of acute myeloid leukemia (Drugs of the Future (2000) 25(7):686; US4970198; US5-79233; US5585089; US5606040; US5693762; US5739116; US5767285; US5773001).

[0007] In August 2011, Adcetris (brentuximab vedotin, Seattle Genetics) passed the US FDA fast-track review channel for the treatment of Hodgkin's lymphoma and relapsed anaplastic large cell lymphoma (Nat. Biotechnol (2003) 21 (7): 778-784; WO2004010957; WO2005001038; US7090843A; US7659241; WO2008025020). It is a new type of targeted ADC drug that can directly act on the target CD30 on lymphoma cells and then induce endocytosis to induce apoptosis of tumor cells. Mylotarg and Adcetris are both targeted therapies for blood tumors, which have a relatively simpler tissue structure than solid tumors. In February 2013, Kadcyla (ado-trastuzumab emtansine, T-DM1) was approved by the US FDA for the treatment of HER-positive advanced and metastatic breast cancer patients who are resistant to trastuzumab (Tratuzumab, trade name: Herceptin) and paclitaxel (WO2005037992; US8088387). Kadcyla is the first ADC drug approved by the US FDA for the treatment of solid tumors.

[0008] In December 2019, DS-8201a (Trastuzumab Deruxtecan, trade name: Enhertu) developed by Daiichi Sankyo was approved by the FDA in the United States for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received more than two HER2-targeted therapies. Enhertu consists of a topoisomerase I inhibitor payload (DXd) connected to a cleavable tetrapeptide linker. The linker is attached to a cysteine ​​residue on the antibody, and the DAR of the ADC is approximately 8. In April 2020, Sacituzumab govitecan (trade name: Immunomedics Inc.) was approved by the FDA for the treatment of triple-negative breast cancer. It targets the tumor-associated calcium signaling 2 (TROP-2) receptor, which is often expressed at high levels in triple-negative breast cancer. The payload SN-38 is a topoisomerase I inhibitor, which is linked to the antibody via a hydrolyzable linker (pH-sensitive linker) CL2A and binds to the antibody via a cysteine ​​residue, and its DAR is 7.6. Both camptothecin ADCs use a coupling strategy with high DAR values.

[0009] As of December 2022, a total of 15 ADC drugs have been approved for marketing worldwide for the treatment of various cancers, including hematological tumors and solid tumors. However, current ADC drugs often have safety defects such as poor water solubility and toxicity caused by high DAR values. In some instances, the design of the compound has a restrictive bystander effect, and the initial degradation products in the targeted tumor cells have a strong bystander effect and have transmembrane ability, which can kill adjacent cells. After being degraded again into auristatin F, it has no transmembrane ability, and the restrictive bystander effect improves the safety of the drug. Therefore, this field still needs to further optimize the molecular structure, improve the water solubility of the conjugated drug, increase the coupling efficiency, and further improve the safety on the basis of increased effectiveness. Summary of the invention

[0010] In the first aspect, the present application provides a compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof,

[0011] PLD (I)

[0012] in,

[0013] P has the following structure:

[0014]

[0015] m and n are each independently selected from any integer from 0 to 12;

[0016] X1 is selected from a bond, a C1-C6 alkylene group, an imino group, an ester group, an amide group, a carbonate group, a carbamate group, a sulfone group, a sulfonamide group, a ketone group, a urea group or a phosphate group;

[0017] X2 is selected from a bond, nitrogen, oxygen, sulfur, phosphorus, a C1-C6 alkylene group, an imino group, an ester group, an amide group, a carbonate group, a carbamate group, a sulfone group, a sulfonamide group, a ketone group, a urea group or a phosphate group;

[0018] L has the following structure:

[0019]

[0020] n1 and n2 are each independently selected from any integer from 1 to 6;

[0021] R1 is selected from a hydrophilic group;

[0022] R2 and R3 are each independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, or R2 and R3 together with the carbon atoms to which they are attached form a C3-C6 cycloalkyl, wherein one or more hydrogen atoms in the C1-C6 alkyl, C1-C6 haloalkyl or C3-C6 cycloalkyl are optionally substituted with halogen, hydroxyl, cyano, amino, C1-C3 alkyl or phenyl;

[0023] R4 is selected from the R group in the α-amino acid general formula R-CH(NH2)COOH;

[0024] R5 is selected from a bond or -Y1-R6-Y2-, wherein Y1 is a bond, -NH- or -O-, Y2 is -NH- or -C=O-, and R6 is selected from -(CH2) z -、-(OCH2) z -、-(CH2O) z -、-(CH2CH2O) z -、-(OCH2CH2) z -, C3-C6 cycloalkyl or a covalently linked combination thereof, z is selected from any integer from 0 to 6; and

[0025] D is a toxin molecule or other equivalent.

[0026] In one embodiment of the present invention, the hydrophilic group may have at least three (e.g., three, four, five or six, etc.) ether bonds and / or hydroxyl groups composed of oxygen-containing groups (the molecular weight of the hydrophilic group is preferably between 100 and 500 Da, such as about 200 Da, 300 Da or 400 Da, etc.), more preferably, the hydrophilic group may have any one of the following structures:

[0027]

[0028] In another embodiment of the present invention, R2 and R3 can be each independently selected from H, F, Cl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or R2 and R3 can form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl together with the carbon atoms to which they are connected, wherein one or more hydrogen atoms in the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl are optionally substituted with halogen, hydroxyl, cyano, amino, C1-C3 alkyl or phenyl.

[0029] In another embodiment of the present invention, R4 can be selected from the R group of glutamic acid, aspartic acid, lysine, arginine, histidine, alanine, valine or tryptophan in α-amino acids (or protein amino acids, basic amino acids, standard amino acids); preferably glutamic acid, aspartic acid or lysine. For example, the R group of glutamic acid is -(CH2)2COOH, and the R group of lysine is -(CH2)4-NH2.

[0030] In another embodiment of the present invention, R5 is selected from a bond, -O-(CH2) z -NH-, -(OCH2) z -NH-, -(OCH2) z -CO-, -(OCH2CH2) z -CO- or -(OCH2CH2) z -NH-, z is selected from any integer from 1 to 3; preferably a bond, -(OCH2) z -CO-, -(OCH2CH2) z -CO- or -(OCH2CH2) z -NH-; further more preferably -(OCH2CH2) z -CO- or -(OCH2CH2) z -NH-.

[0031] In another embodiment of the present invention, according to functional classification, the toxin molecule can be a microtubule disruptor, an anti-mitotic inhibitor or a DNA damaging drug, etc.; or according to structural classification, the toxin molecule can be a toxin molecule such as maytansine, auristatin, paclitaxel, anthramycin, calicheamicin, duocarmycin, camptothecin or amanita muscaria.

[0032] In a preferred embodiment of the present invention, the toxin molecule may be an auristatin F derivative having the following structure:

[0033]

[0034] In another preferred embodiment of the present invention, the toxin molecule may be an isotecan analog having the following structure:

[0035]

[0036] For the sake of simplicity, the "compound of formula (I)" or "compound of the present application" mentioned below may also include any isotope-labeled compound of the compound of formula (I), or its optical isomers, geometric isomers, tautomers or isomer mixtures, or its pharmaceutically acceptable salts, or its prodrugs, or its metabolites.

[0037] The term "optical isomer" means that when a compound has one or more chiral centers, each chiral center may exist in the R configuration or the S configuration, and the various isomers thus constituted are optical isomers. Optical isomers include all diastereomers, enantiomers, mesomers, racemates or mixtures thereof. For example, optical isomers can be separated by chiral chromatography or by chiral synthesis.

[0038] The term "geometric isomer" means that when a double bond exists in a compound, the compound may exist as cis isomers, trans isomers, E isomers and Z isomers. Geometric isomers include cis isomers, trans isomers, E isomers, Z isomers or a mixture thereof.

[0039] The term "tautomer" refers to an isomer that is produced by the rapid movement of an atom in a molecule between two positions. Those skilled in the art will understand that tautomers can transform into each other and may reach an equilibrium state and coexist under a certain state.

[0040] Unless otherwise indicated, references herein to "compounds of formula (I)" or "compounds of the present invention" also encompass isotope-labeled compounds in which any atom in the compound is replaced by its isotope atom. The present invention includes all pharmaceutically acceptable isotope-labeled compounds of compounds of formula (I), wherein one or more atoms are replaced by atoms having the same atomic number as the atoms usually found in nature but with a different atomic mass or mass number.

[0041] Examples of suitable isotopes for inclusion in the compounds of the present invention include isotopes of hydrogen such as 2 H(D) and 3 H(T), isotopes of carbon, such as 11 C. 13 C and 14 C, isotopes of chlorine, such as 37 Cl, isotopes of fluorine, such as 18 F, isotopes of iodine, such as 123 I and 125 I, isotopes of nitrogen, such as 13 N and 15 N, isotopes of oxygen, such as 15 O. 17 O and 18 O, and isotopes of sulfur such as 35 S.

[0042] Isotopically labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by using an appropriate isotopically labeled reagent in place of the non-labeled reagent previously used in an analogous manner to the methods described in the Examples and Preparations appended herein.

[0043] The compounds of formula (I) may exist in the form of pharmaceutically acceptable salts, for example, acid addition salts and / or base addition salts of the compounds of formula (I). Unless otherwise indicated, "pharmaceutically acceptable salts" as used herein include acid addition salts or base addition salts that may occur in the compounds of formula (I).

[0044] Pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts and base addition salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include, but are not limited to, acetate, adipate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, cyclaminate, edisylate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, 2-(4-hydroxybenzyl)benzoate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, 2-hydroxyethanesulfonate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthoate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, hexadecanoate, phosphate / hydrogenphosphate / dihydrogenphosphate, pyroglutamate, glucarate, stearate, salicylate, tannate, tartrate, toluenesulfonate, and trifluoroacetate. Suitable base addition salts are formed from bases which form non-toxic salts. Examples include, but are not limited to, aluminum, arginine, calcium, choline, diethylamine, diethanolamine, glycine, lysine, magnesium, meglumine, ethanolamine, potassium, sodium, tromethamine, and zinc salts. Hemi-salts of acids and bases, such as hemi-sulfate and hemi-calcium salts, can also be formed. For a review of suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection and Use by Stahland Wermuth (Wiley-VCH, 2002). Methods for preparing pharmaceutically acceptable salts of the compounds described herein are known to those skilled in the art.

[0045] Certain compounds of the present invention may exist in unsolvated forms as well as solvated forms (including hydrated forms). In general, compounds of formula (I) are encompassed within the scope of the present invention regardless of whether they exist in solvated or unsolvated forms.

[0046] Certain compounds of the present invention may exist in different crystalline or amorphous forms. Regardless of the form in which they exist, the compounds of formula (I) are included within the scope of the present invention.

[0047] To avoid ambiguity, the following definitions are given for the terms used in this article. Unless otherwise specified, the meanings of the terms used in this article are as follows.

[0048] The term "pharmaceutically acceptable" means that the corresponding compound, carrier or molecule is suitable for administration to humans. Preferably, the term refers to any national regulatory agency certified by regulatory agencies such as CFDA (China), EMEA (Europe), FDA (USA) for use in mammals, preferably humans.

[0049] "Prodrug" refers to a derivative that is converted into the compound of the present invention by reaction with an enzyme, gastric acid, etc. under physiological conditions in vivo, for example, by oxidation, reduction, hydrolysis, etc., each catalyzed by an enzyme.

[0050] "Metabolites" refers to all molecules derived from any compound of the invention in a cell or organism, preferably a human.

[0051] As used herein, the term "substituted" means that one or more (preferably 1 to 5, more preferably 1 to 3) hydrogen atoms in the group are independently replaced by a corresponding number of substituents.

[0052] As used herein, the term "independently" means that when there are more than one substituent, the substituents may be the same or different.

[0053] As used herein, the term "optional" or "optionally" means that the event it describes can or cannot occur. For example, a group "optionally substituted" means that the group can be unsubstituted or substituted.

[0054] As used herein, the term "alkyl" refers to a saturated aliphatic hydrocarbon, including straight and branched chains. In some embodiments, the alkyl group has 1-8, or 1-6, or 1-3 carbon atoms. For example, the term "C 1-8 "Alkyl" refers to a straight or branched chain radical having 1 to 8 carbon atoms. 1-8 The term "alkyl" includes in its definition the term "C 1-6 Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, isopentyl, neopentyl, (R)-2-methylbutyl, (S)-2-methylbutyl, 3-methylbutyl, 2,3-dimethylpropyl, 2,3-dimethylbutyl, hexyl, and the like. The alkyl group may be optionally substituted with one or more (e.g., 1 to 5) suitable substituents.

[0055] As used herein, the term "haloalkyl" refers to an alkyl group having one or more halogen substituents (up to a perhaloalkyl group, i.e., each hydrogen atom of the alkyl group is replaced by a halogen atom). For example, the term "C1-C6 haloalkyl" refers to a C1-C6 haloalkyl group having one or more halogen substituents.1-6 Alkyl groups (up to perhaloalkyl groups, i.e., each hydrogen atom of the alkyl group is replaced by a halogen atom). As another example, the term "C1-C4 haloalkyl" refers to a C1-C4 haloalkyl group having one or more halogen substituents. 1-4 Alkyl groups (up to perhaloalkyl groups, i.e., each hydrogen atom of the alkyl group is replaced by a halogen atom); the term "C 1-3 "Haloalkyl" refers to a C 1-3 alkyl group (up to a perhaloalkyl group, i.e., each hydrogen atom of the alkyl group is replaced by a halogen atom); and the term “C 1-2 "Haloalkyl" refers to a C 1-2 Alkyl groups (i.e., methyl or ethyl) (up to perhaloalkyl, i.e., each hydrogen atom of the alkyl group is replaced by a halogen atom). As another example, the term "C1 haloalkyl" refers to a methyl group having 1, 2 or 3 halogen substituents. Examples of haloalkyl groups include: CF3, C2F5, CHF2, CH2F, CH2CF3, CH2Cl, etc.

[0056] As used herein, the term "C3-C6 cycloalkyl group" refers to a cycloalkyl group having 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0057] Herein, the numerical ranges related to the number of substituents, the number of carbon atoms, and the number of ring atoms represent a list of all integers within the range, and the ranges are only used as a simplified representation. For example, "1-4 substituents" means 1, 2, 3, or 4 substituents; "3-8 ring atoms" means 3, 4, 5, 6, 7, or 8 ring atoms. Therefore, the numerical ranges related to the number of substituents, the number of carbon atoms, and the number of ring atoms also include any subranges thereof, and each subrange is also deemed to be disclosed herein.

[0058] The compounds of the present application can be prepared in a variety of ways known to those skilled in the art of organic synthesis. Those skilled in the art can refer to the synthetic routes of the specific compounds of the specific embodiments of the present application and make appropriate adjustments to the reaction raw materials and reaction conditions to obtain synthetic methods for other compounds.

[0059] In a second aspect, the present application provides a conjugate, which includes a compound according to the aforementioned formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof as a conjugation precursor of the conjugate.

[0060] In one embodiment of the invention, the conjugate includes a targeting moiety. As used herein, the term "targeting moiety" is a chemical moiety that is capable of binding to a biological entity, such as an antibody, a synthetic functionalized antibody, an enzyme, a protein or a peptide, or any other targeting ligand. The targeting moiety can localize a therapeutic agent or a small molecule to a specific targeting site, such as a tumor or tissue. This can effectively increase the efficacy of the therapeutic agent at the targeting site while minimizing the unwanted side effects to normal cells.

[0061] In one embodiment of the present invention, the targeting moiety may include, but is not limited to, antibodies or synthetic functionalized antibodies specific for an antigen selected from the group consisting of HER2, EGFR, Claudin18.2, c-MET, Nectin-4, ROR1, GPNMB, CD56, TACSTD2 (TROP2), CEACAM5, folate receptor-α, mesothelin, ENPP3, guanylate cyclase C, SLC44A4, NaPi2b, CD70, mucin 1, STEAP1, connexin 4, 5T4, SLTRK6, SC-16, LIV-1, P-cadherin, PSMA, fibronectin extracellular domain B, endothelin receptor ETB, tenascin c, collagen IV, VEGFR2, periostin, CD30, CD79b, CD19, CD22, CD138, CD37, CD33, CD74, CD19 and CD98. In a preferred embodiment of the present invention, the targeting moiety may be trastuzumab or synthetically functionalized trastuzumab.

[0062] In one embodiment of the invention, the targeting moiety can be coupled to the maleimide group of the compound of formula (I) by reducing the interchain disulfide bond to form a free sulfhydryl group (i.e., by -S-). In a preferred embodiment of the invention, the DAR value of the antibody conjugate is any integer or decimal in 1-10, preferably 4-8 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or any decimal therebetween, preferably, the DAR value is 4-8, more particularly 6.9, 7.45, etc.). When used herein, the term "DAR value" represents the average number of toxin molecules connected to each monoclonal antibody.

[0063] In a third aspect, the present application provides a pharmaceutical composition comprising a compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, or a conjugate thereof; and a pharmaceutically acceptable carrier.

[0064] Pharmaceutically acceptable carriers can be organic or inorganic inert carrier materials, for example, suitable carriers include water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, vaseline, mannitol, cellulose, cellulose derivatives, saccharin sodium, glucose, sucrose, magnesium carbonate, saline, glycerol, ethanol, etc. In addition, the pharmaceutical composition may also contain other pharmaceutical additives, such as flavoring agents, preservatives, stabilizers, emulsifiers, buffers, diluents, binders, wetting agents, disintegrants, lubricants, glidants, etc.

[0065] The dosage form of the pharmaceutical composition of the present application can be a liquid dosage form, a solid dosage form or a semi-solid dosage form. The liquid dosage form can be a solution (including a true solution and a colloidal solution), an emulsion (including an o / w type, a w / o type and a multiple emulsion), a suspension, an injection (including a water injection, a powder injection and an infusion), an eye drop, a nasal drop, a lotion and an liniment, etc.; the solid dosage form can be a tablet (including a common tablet, an enteric-coated tablet, a lozenge, a dispersible tablet, a chewable tablet, an effervescent tablet, an orally disintegrating tablet), a capsule (including a hard capsule, a soft capsule, an enteric-coated capsule), a granule, a powder, a pill, a suppository, a film, a patch, an aerosol, a spray, etc.; the semi-solid dosage form can be an ointment, a gel, a paste, etc. The pharmaceutical composition of the present application can be made into a common preparation, a sustained-release preparation, a controlled-release preparation, a targeted preparation and various microparticle delivery systems.

[0066] In some embodiments, the dosage form of the pharmaceutical composition is selected from tablets, capsules, granules, powders, syrups, inhalants and injections.

[0067] Solid dosage forms for oral administration may include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is mixed with at least one inert excipient (or carrier) (e.g., sodium citrate or dicalcium phosphate), which may also include: (a) fillers or admixtures (e.g., starch, lactose, sucrose, glucose, mannitol and silicic acid); (b) binders (e.g., carboxymethylcellulose, alginate, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic); (c) humectants (e.g., glycerol); (d) disintegrants (e.g., agar); The invention can be prepared by mixing (a) agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain synthetic silicates, sodium carbonate); (e) solution retarder (e.g., paraffin); (f) absorption promoter (e.g., quaternary ammonium compounds); (g) wetting agents (e.g., cetyl alcohol and glycerol monostearate); (h) adsorbents (e.g., kaolin and bentonite) and (i) lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate) or mixtures thereof.

[0068] Preparations suitable for parenteral administration, such as injections, may include aqueous and non-aqueous isotonic sterile solutions suitable for injection, as well as aqueous and non-aqueous sterile suspensions. The parenteral formulations provided herein are optionally contained in unit dose or multi-dose sealed containers (e.g., ampoules), and can be stored under freeze drying (lyophilization) conditions that require only the addition of a sterile liquid carrier (e.g., water for injection) just before use. Examples of suitable diluents for reconstructing pharmaceutical compositions (e.g., before injection) include antibacterial water for injection, 5% glucose aqueous solution, phosphate buffered saline, Ringer's solution, saline, sterile water, deionized water, and combinations thereof.

[0069] Sprays may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances. Sprays may additionally contain conventional propellants, such as chlorofluorocarbons and volatile unsubstituted hydrocarbons, such as butane and propane. Inhalants may contain excipients such as lactose, or aqueous solutions containing, for example, polyethylene oxide-9-lauryl ether, glycocholate and deoxycholate, or oily solutions administered as nasal drops or sprays, or in the form of gels.

[0070] The content of the compound of the present application in its pharmaceutical composition can be adjusted according to actual needs (such as dosage form, administration method, administration object, etc.), for example, 0.1-95% by weight, such as 1-95% by weight, 5-90% by weight, 10-80% by weight, etc.

[0071] Specifically, the pharmaceutical composition of the present application may specifically contain 0.001-10 g (eg, 0.05 g, 0.1 g, 0.5 g, 1 g or 5 g, etc.) of the compound of the present application.

[0072] In a fourth aspect, the present application provides a compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, or the use of the above-mentioned conjugate in the preparation of a drug for treating or preventing cancer in a subject in need thereof. A compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, or the above-mentioned conjugate can be used to treat or prevent the cancer in a subject in need thereof.

[0073] The term "subject" as used herein refers to any human or non-human organism that can potentially benefit from treatment with a compound of formula (I). Exemplary subjects include humans or mammals of any age. Preferably, the subject is a human.

[0074] As used herein, the term "treatment" includes treating a disease or symptom in a mammal, particularly a human, and includes: (a) inhibiting an infection, disease or symptom, i.e., arresting or delaying the development of an infection, disease or symptom; (b) alleviating an infection, disease or symptom, i.e., causing regression of the disease or symptom, and / or (c) curing an infection, disease or symptom.

[0075] As used herein, the term "prevention" includes prophylactic therapy in mammals, especially humans, to reduce the likelihood of infection, disease or symptoms. Patients who receive prophylactic therapy can be selected based on their increased risk of infection or disease or symptoms compared to the general population. "Prevention" can include treatment of subjects who have not yet presented with an infection or clinical condition, and preventing the second occurrence of the same or similar infection or clinical condition.

[0076] In one embodiment of the present invention, the cancer may be various cancers known in the art, including but not limited to, for example, bone cancer, brain cancer, breast cancer, cervical cancer, laryngeal cancer, lung cancer, pancreatic cancer, prostate cancer, skin cancer, spinal cancer, stomach cancer, uterine cancer, and / or lymphoma, etc. In a preferred embodiment of the present invention, the cancer may be a HER2-positive cancer. In a more preferred embodiment of the present invention, the HER2-positive cancer may be a cancer in which HER2 is overexpressed. In a further preferred embodiment of the present invention, the cancer may be breast cancer.

[0077] In a fifth aspect, the present application provides a method for treating or preventing cancer, the method comprising administering a therapeutically effective amount of the above-mentioned drug or pharmaceutical composition of the present invention to a subject in need thereof.

[0078] In some embodiments, the compounds of the present invention can be administered orally, parenterally, intravenously, intramuscularly, subcutaneously, nasally, oral mucosa, ocularly, pulmonary, respiratory, vaginally, rectally, intraperitoneally, intralesionally, perilesionally, and the like.

[0079] "Therapeutically effective amount" refers to an amount of the compound of the present application that is effective in treating or preventing cancer, inhibiting cancer cell proliferation, and / or reducing tumor volume when administered alone or in combination.

[0080] The specific dosage will depend on the route of administration, the severity of the disease, the age and weight of the patient, and other factors that the attending physician generally considers when determining the individual regimen and dosage level that is most suitable for a particular patient. For example, the daily dose of the compound of the present application can be particularly 0.001-150 mg / kg body weight (e.g., 0.1 mg / kg body weight, 1 mg / kg body weight, 10 mg / kg body weight or 100 mg / kg body weight, etc.).

[0081] The specific administration frequency can be determined by technicians in the relevant field, for example, once a day, once every two days, once every three days, once every four days, once every five days, once every six days, twice a day, three times a day, etc.

[0082] Those skilled in the art will appreciate that the definitions and preferences described in one aspect of the present application are equally applicable to other aspects. Those skilled in the art will appreciate that the embodiments of various aspects of the present application can be combined in various ways without departing from the subject matter and ideas of the present application, and these combinations are also included in the scope of the present application. BRIEF DESCRIPTION OF THE DRAWINGS

[0083] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the following specific embodiments, they are used to explain the present invention, but do not constitute a limitation of the present invention. In the accompanying drawings:

[0084] Figure 1 shows the growth curve of the tumor volume of each group of mice in the subcutaneous xenograft model of human breast cancer JIMT-1 according to one embodiment of the present invention, wherein the data are expressed as "mean ± standard error"; and

[0085] Figure 2 The figure shows the body weight change curves of each group over the treatment time in the human breast cancer JIMT-1 subcutaneous xenograft model according to one embodiment of the present invention, wherein the data are expressed as “mean ± standard error”. DETAILED DESCRIPTION

[0086] The compounds of formula (I) of the present application can be synthesized by various methods familiar to those skilled in the art of organic synthesis. Some exemplary synthesis methods of compounds of formula (I) are given in the following specific examples, and these methods are well known in the field of synthetic chemistry. Obviously, referring to the exemplary schemes in this patent, those skilled in the art can easily design the synthesis routes of other compounds of formula (I) by appropriately adjusting the reactants, reaction conditions and protecting groups.

[0087] The present invention is further described below with reference to the examples; however, these examples do not limit the scope of the present invention. Unless otherwise stated, all reactants used in the examples are obtained from commercial sources; the instruments and equipment used in the synthesis experiments and product analysis and detection are conventional instruments and equipment commonly used in organic synthesis.

[0088] The structure of the compound was determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR was measured using a Bruker AVANCE-400 NMR spectrometer, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDC13), deuterated methanol (CD3OD), deuterated water (D2O) as the internal standard, and the chemical shift was 10-6 (ppm) is given as a unit. MS was determined using a Waters (ESI) mass spectrometer (model: Acquity H-Class LC-MS). HPLC was determined using an Agilent 1260infinity II high pressure liquid chromatograph. The preparative liquid phase was prepared using a Waters Prep-HPLC high pressure liquid phase preparative chromatograph (Unitary C18 250×20mm column). Normal phase preparation was performed using a Biotage Selekt chromatography purification system.

[0089] Abbreviations used herein have the definitions shown in Table 1 below.

[0090] Table 1

[0091]

[0092]

[0093] Example 1: Preparation of Compound DL-1

[0094]

[0095] Step 1: Synthesis of 2-(2-((S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)3-phenylpropionamido(ethoxy)ethyl(tert-butoxycarbonyl)-L-valine

[0096] Compound 1 (181 mg, 0.217 mmol) and compound Boc-valine (236 mg, 1.086 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature to dissolve, and then placed in an ice bath. DIEA (450 uL, 2.713 mmol), HOBT (205 mg, 1.519 mmol), and EDCI (262 mg, 1.367 mmol) were added in sequence at 0-5 °C. The reaction was carried out at 0-5 °C for 3 hours, and then at room temperature for 12 hours. LCMS showed that the reaction was completed when the compound 1 in the reaction solution was less than 3%. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in sequence. The organic phases were combined after two extractions, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The crude product was separated and purified by silica gel column chromatography using 10% MeOH / DCM. Compound 2 (white solid, 320 mg, yield 143%) was prepared. MS: 1033.38 [M+H] + .

[0097] Step 2: Synthesis of ethyl 2-(2-((S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)3-phenylpropionamido(ethoxy)L-valine Compound 2 (320 mg, 0.31 mmol) was placed in a 25 mL single-necked bottle, and dichloromethane (5 mL) and HCl / 1,4-dioxane solution (2 ml, 4 M) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored the reaction of the raw material compound 3. After spin drying, compound 3 (white solid, 337 mg, yield 116.6%) was obtained. MS: 933.26 [M+H] + .

[0098] Step 3: Synthesis of tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,18-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazanonan-17-yl)amino)-5-oxopentanoate

[0099] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (46 mg, 0.107 mmol) and HATU (49 mg, 0.107 mmol) were added to N,N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, then DIEA (71 uL, 0.428 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 3 (100 mg, 0.107 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 3 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by silica gel column chromatography using MeOH / DCM to obtain compound 4 (white solid, 128 mg, yield 89%). MS: 670.86 [M+2H] 2+ / 2.

[0100] Step 4: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1)-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,18-dimethyl-5,8,16-trioxo-2,12,15-trioxo-6,9-diazanonadecan-17-yl)amino)-5-oxopentanoate

[0101] Compound 4 (128 mg, 0.096 mmol) was placed in a 25 mL single-mouth bottle, and N, N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 4 was complete. The reaction solution was evaporated under reduced pressure to dry the solvent, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 5 (white solid, 24 mg, yield 22.6%) was obtained. MS: 1118.48 [M+H] + .

[0102] Step 5: Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-((S)-1-((3R,4S,5S))-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isopropyl-4-methyl-5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid

[0103] Compound 3-Boc-aminoglutaric acid (11 mg, 0.043 mmol) and HATU (20 mg, 0.052 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, then DIEA (28 uL, 0.172 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 5 (24 mg, 0.021 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 5 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 6 (white solid, 17 mg, yield 58.8%) was prepared. MS: 674.36 [M+2H] 2+ / 2.

[0104] Step 6: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazepan-14-yl(10S,13S)-10-(3-(tert-butoxy)-3-oxopropyl)-13-isopropyl-2,2-dimethyl-6-(2-(methyl((2S,3R,4R,5R)-2,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,8,11-trioxo-3-oxo-5,9,12-triazatetradecane-14-oate

[0105] Compound meglumine (17 mg, 0.013 mmol) and HATU (5.7 mg, 0.015 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, then DIEA (8 uL, 0.051 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 6 (7.4 mg, 0.038 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction liquid contained less than 3% of compound 6, and the reaction was considered to be complete. The reaction liquid was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 7 (white solid, 11 mg, yield 57.9%) was prepared. MS: 763.95 [M+2H] 2+ / 2.

[0106] Step 7: Synthesis of (3R,4R,7S,17S,20S)-20-(3-amino-5-(methyl((2S,3R,7R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamide)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isopropyl-4-methyl-5,8,16,19-tetraoxo-2,12,15-trioxa-6,9,18-triazatriazole-23-octanoic acid

[0107] Compound 7 (11 mg, 0.0072 mmol) was added with dichloromethane (2 mL) and HCl / 1,4-dioxane solution (1 ml, 4 M), and reacted at room temperature for 1 h. LCMS monitored that the reaction of the raw material was complete. After spin drying, compound 8 (white solid, 17 mg, yield 173.5%) was obtained. MS: 684.84 [M+2H] 2+ / 2.

[0108] Step 8: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,18-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazanonadecan-1 Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,3-(2-(methyl((2S,3R,5R)-2,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetraenoic acid

[0109] Add the compound maleimide octaethylene glycol propionic acid (7.4 mg, 0.0124 mmol) and HATU (5.7 mg, 0.0149 mmol) to N, N-dimethylformamide (2 mL), stir at room temperature for 10 minutes, then add DIEA (6.4 uL, 0.0496 mmol) and stir at room temperature for 10 minutes, finally add compound 8 (17 mg, 0.0124 mmol) and stir at room temperature for 3 hours. LCMS shows that the reaction is completed when the compound 8 in the reaction solution is less than 3%. The reaction solution is evaporated to dryness, and the crude product is separated and purified by preparative liquid phase separation with acetonitrile / water. Freeze-dried to obtain compound DL-1 (white solid, 7 mg, yield 29.2%). MS: 1943.31 [M+H] +

[0110] 1 H NMR(400MHz,D2O)δ7.36–7.11(m,5H),6.79(s,2H),4.24(s,5H),4.01(s,2H),3.71(m,5H),3.67(m,4H ),3.62(m,14H),3.61(m,5H),3.60–3.55(m,7H),3.48(m,3H),3.30(s,2H),3.25(m,6H),3.14(s,1H), 3.12(s,1H),3.08(s,2H),3.05m,1H),2.85(m,2H),2.55–2.36(m,7H),2.35–2.06(m,6H),1.78(m,4H) ,1.57(s,4H),1.26(m,5H),1.12(m,1H),1.03(m,3H),0.94(m,8H),0.85(d,J=5.6Hz,8H),0.78(m,4H).

[0111] Example 2: Preparation of Compound DL-2

[0112]

[0113] Step 1: Synthesis of tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate

[0114] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (71 mg, 0.166 mmol) and HATU (75 mg, 0.197 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, then DIEA (110 uL, 0.667 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 9 (150 mg, 0.166 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when compound 9 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and the crude product was separated and purified by silica gel column chromatography using 3% MeOH / DCM. Compound 10 (white solid, 177 mg, yield 81%) was prepared. MS: 656.8 [M+2H] 2+ / 2

[0115] Step 2: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate

[0116] Compound 10 (177 mg, 0.135 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 10 was complete. After spin drying, a white solid was obtained, which was then repeatedly washed with 50 mL of petroleum ether to remove impurities, and compound 11 (white solid, 150 mg, yield 102%) was obtained. MS: 1090.43 [M+H] +

[0117] Step 3:

[0118] Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-(S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid

[0119] Compound 3-Boc-aminoglutaric acid (41 mg, 0.165 mmol) and HATU (63 mg, 0.165 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, then DIEA (92 uL, 0.552 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 11 (150 mg, 0.138 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 11 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 12 (white solid, 121 mg, yield 66.5%) was prepared. MS: 660.33 [M+2H] 2+ / 2

[0120] Step 4: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazo Synthesis of tetradecane-14-yl (10S,13S)-10-(3-(tert-butoxy)-3-oxopropyl)-2,2,13-trimethyl-6-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,811-trioxy-3-oxo-5,9,12-triazatetradecane-14-yl ester

[0121] Compound meglumine (134 mg, 0.102 mmol) and HATU (47 mg, 0.122 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, then DIEA (92 uL, 0.552 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 12 (150 mg, 0.138 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when compound 12 was less than 3% in the reaction solution. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 13 (white solid, 124 mg, yield 81.3%) was prepared. MS: 748.93 [M+2H] 2+ / 2

[0122] Step 5: Synthesis of (3R,4R,7S,17S,20S)-20-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamido)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19-tetraoxo-2,12,15-trioxo-6,9,18-triazatriazole-23-oic acid

[0123] Compound 13 (124 mg, 0.083 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (5 mL) and HCl / ethyl acetate solution (1 ml, 4 M) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 13 was complete. A white solid was obtained after spin drying. The crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Freeze drying gave compound 14 (white solid, 100 mg, yield 89.9%). MS: 670.82 [M+2H] 2+ / 2

[0124] Step 6: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)carbamoyl 1-(2,5-dioxy-2,5-dihydro-1H-pyrrolidin-1-yl)-33-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,31,31,35-trioxy-7,10,13,16,19,22,25,28-octaoxy-4,32,3,6-triazatetracarboxylic acid

[0125] The compound maleimide octaethylene glycol propionic acid (2.8 mg, 0.0047 mmol) and HATU (2.2 mg, 0.0057 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (3.1 uL, 0.0187 mmol) was added and stirred at room temperature for 10 minutes. Finally, compound 14 (7 mg, 0.0052 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 14 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by preparative liquid phase separation with acetonitrile / water. Freeze-dried to obtain compound DL-2 (white solid, 2 mg, yield 20.1%). MS: 1915.26 [M+H] +

[0126] 1H NMR(400MHz,D2O)δ7.32–7.26(m,1H),7.23(d,J=4.8Hz,4H),6.79(s,2H),4.66(m,1H),4.61(m,2H),4.27–4.14(m,4H),3.81–3.69(m, 6H),3.66(m,6H),3.62(m,16H),3.61(m,6H),3.58(m,10H),3.54(s,2H),3.48(m,3H),3.45–3.40(m,2H),3.37(m,3H),3.30(s,2H),3. 28–3.20(m,8H),3.20–3.13(m,2H),3.10(m,3H),3.05(m,2H),2.92–2.79(m,9H),2.71–2.58(m,3H),2.50(d,J=15.7Hz,2H),2.42(m,7 H),2.26(s,4H),1.80(m,4H),1.35(d,J=7.3Hz,6H),1.12(d,J=6.7Hz,2H),1.03(m,4H),0.95(m,10H),0.87(m,5H),0.82–0.72(m,4H).

[0127] Example 3: Preparation of Compound DL-3

[0128]

[0129] Step 1: Synthesis of ethyl 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamide)-3-phenylpropanamide)ethoxy)L-alanine

[0130] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (47.2 mg, 0.111 mmol) and HATU (51 mg, 0.133 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, and then DIEA (56 μL, 0.333 mmol) and compound 9 (100 mg, 0.1111 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 9 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and then separated and purified by silica gel column chromatography with 3% MeOH / DCM. Compound 10 (white solid, 130 mg, yield 90%) was prepared. MS: 628.57 [M-tBu] 2+ .

[0131] Step 2: Synthesis of tert-butyl (S)-4-amino-5-((((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate

[0132] Compound 10 (130 mg, 0.099 mmol) was added to N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) and reacted at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 10 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50*3 mL of petroleum ether to remove impurities to obtain compound 11 (white solid, 101 mg, yield 93.5%). MS: 1090.60 [M+H] + .

[0133] Step 3: Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-((S)-1-((3R,4S,5S)-4-((S-2-((S)-2(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid

[0134] Compound 3-Boc-aminoglutaric acid (25.2 mg, 0.102 mmol) and HATU (42.6 mg, 0.112 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (46.2 μL, 0.279 mmol) and compound 11 (101 mg, 0.093 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when the compound 11 in the reaction solution was less than 3%. The reaction solution was distilled under reduced pressure to remove the solvent, and purified by preparative liquid separation (acetonitrile / water). Compound 12 (white solid, 102 mg, yield 83.3%) was prepared. MS: 643.70 [M+Na-tBu] 2+ .

[0135] Step 4: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaanthen-14-yl(18S,21S)-18-(3-(tert-butoxy)-3-oxopropyl)-14-(tert-butoxycarbonyl)amino)-21-methyl-12,16,19-trioxy-2,5,8-trioxa-11,17,20-triazapolyoxane-22-oic acid ester

[0136] Compound 12 (31 mg, 0.0235 mmol) and HATU (10.7 mg, 0.0282 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (12.8 μL, 0.0705 mmol) and compound methyl-triethylene glycol-amine (7.7 mg, 0.0470 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 12, which was considered to be the end of the reaction. The reaction liquid was distilled under reduced pressure to remove the solvent, and purified by preparative liquid separation (acetonitrile / water). Compound 15 (white solid, 21 mg, yield 61.0%) was prepared. MS: 682.63 [M-Boc] 2+ .

[0137] Step 5: Synthesis of (3R,4R,7S,17S,20S)-20-(14-amino-12-oxo-2,5,8-trioxa-11-hexadecane-16-amino)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19-tetraoxo-2,12,15-trioxo-6,9,18-triazatriazole-23-oic acid

[0138] Compound 15 (21 mg, 0.0144 mmol) was added with dichloromethane (2 mL) and hydrochloric acid ethyl acetate solution (1 ml, 4 M), and reacted at room temperature for 1 h. LCMS monitored the complete reaction of the raw material compound 15. The solvent was removed by distillation under reduced pressure, and the product was separated and purified by preparative liquid phase separation (acetonitrile / water). Compound 16 (white solid, 8.0 mg, yield 42.6%) was prepared. MS: 654.58 [M+2H] 2+ / 2.

[0139] Step 6: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,1 Synthesis of 1-(5-trioxy-6,9-diazaoctadecane-17-yl)carbamoyl)-1-(2,5-dioxy-2,5-dihydro-1H-pyrrolidin-1-yl)-3,31,35-trioxy-33-(12-2,5,8-trioxy-11-azatridecan-13-yl)-7,13,16,19,22,25,28-octaoxy-4,32,36-triazacyclopentane-40 acid

[0140] The compound maleimide octaethylene glycol propionic acid (3.6 mg, 0.0061 mmol) and HATU (2.7 mg, 0.0061 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (3.1 μL, 0.0187 mmol) and compound 16 (8.0 mg, 0.0061 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 16, and the reaction was considered to be complete. The reaction liquid was distilled under reduced pressure to remove the solvent, and purified by preparative liquid phase separation (acetonitrile / water). The preparative freeze-dried compound DL-3 (white solid, 6.0 mg, yield 52.0%) was obtained, MS: 1883.26 [M+H]+ .

[0141] 1 H NMR (400MHz, DMSO-d6) δ8.40(s,1H),8.09–7.90(m,4H),7.83(d,J=5.9Hz,1H),7.68(d,J=8.2Hz,1H),7.30–7.17(m,4H),7.14( s,1H),7.00(s,2H),4.65(m,3H),4.54(m,2H),4.29(m,3H),4.12(m,3H),3.97(s,2H),3.77(m,1H),3.58(m,7H),3.50(m,31H), 3.45–3.35(m,9H),3.27–3.10(m,13H),3.07(s,1H),3.01(m,3H),2.82–2.64(m,3H),2.46–2.41(m,2H),2.33(m,6H),2.26(m,7 H),1.99(m,4H),1.74(m,5H),1.37–1.18(m,5H),1.15(s,1H),1.03(d,J=6.6Hz,2H),1.01–0.81(m,13H),0.75(t,J=7.2Hz,6H).

[0142] Example 4: Preparation of Compound DL-4

[0143]

[0144] Step 1: Synthesis of ethyl 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamide)-3-phenylpropanamide)ethoxy)L-alanine

[0145] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (98.7 mg, 0.232 mmol) and HATU (92.4 mg, 0.243 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, and then DIEA (110 μL, 0.663 mmol) and compound 9 (200 mg, 0.221 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 9 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and then separated and purified by silica gel column chromatography with 3% MeOH / DCM. Compound 10 (white solid, 210 mg, yield 72.4%) was prepared. MS: 628.56 [M-tBu] 2+ .

[0146] Step 2: Synthesis of tert-butyl (S)-4-amino-5-((((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate

[0147] Compound 10 (210 mg, 0.160 mmol) was added to N,N-dimethylformamide (5 mL) and piperidine (0.5 ml), and the reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 10 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50 mL*3 petroleum ether to remove impurities to obtain compound 11 (white solid, 160 mg, yield 91.8%). MS: 1090.59 [M+H] + .

[0148] Step 3: (3R,4R,7S,17S,20S,28R)-24-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-7-benzyl-20-(3-(tert-butyloxy)-3-oxopropyl)-3-((S)-1-((3R,4S,5S)-4-(((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido Synthesis of ((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,12,15-trioxy-6,9,18,21,27-pentaazanonane-29-oic acid)-(((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,17-dimethyl-5,8,16,19,22,26-hexaoxy-28-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,12,15-trioxy-6,9,18,21,27-pentaazanonane-29-oic acid)

[0149] Compound 3-Fmoc-aminoglutaric acid (108.6 mg, 0.294 mmol) and HATU (55.9 mg, 0.147 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (72.9 μL, 0.441 mmol) and compound 11 (160 mg, 0.147 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when the compound 11 in the reaction solution was less than 3%. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid separation (acetonitrile / water). Compound 17 (white solid, 125 mg, yield 59.1%) was prepared. MS: 693.14 [M-tBu+2H] 2+ .

[0150] Step 4: Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-((S)-1-((3R,4S,5S)-4-((S-2-((S)-2(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid

[0151] Compound 17 (60 mg, 0.042 mmol) and HATU (17.5 mg, 0.046 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (20.9 μL, 0.126 mmol) and compound D-glucosamine hydrochloride (15.1 mg, 0.084 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 17, and the reaction was considered to be complete. The reaction liquid was distilled under reduced pressure to remove the solvent, and purified by preparative liquid separation (acetonitrile / water). Compound 18 (white solid, 42 mg, yield 63.0%) was prepared. MS: 800.87 [M+2H] 2+ / 2.

[0152] Step 5: Synthesis of tert-butyl (4S)-4-(3-amino-5-oxo-5-(((3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)pentamido)-5-((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate

[0153] Compound 18 (42 mg, 0.026 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 ml) and reacted at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 18 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50*3 mL of petroleum ether to remove impurities to obtain compound 19 (white solid, 25 mg, yield 69.0%). MS: 690.64 [M+2H] 2+ / 2.

[0154] Step 6: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaanthen-14-yl (2S,5S)-5-(3-(tert-butyloxy)-3-oxopropyl)-41-(2 Synthesis of 2-((((3R,4R,5S,6R)-2,4,5-trihydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)ethyl)-14,17,20,23,26,29,32,35-octaoxa-3,6,10,38-tetraazatetraenoic acid

[0155] The compound maleimide octaethylene glycol propionic acid (11 mg, 0.018 mmol) and HATU (7.3 mg, 0.019 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (8.9 μL, 0.054 mmol) and compound 19 (25 mg, 0.018 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 19, and the reaction was considered to be complete. The reaction liquid was distilled under reduced pressure to remove the solvent, and purified by preparative liquid phase separation (acetonitrile / water). The preparative freeze-dried compound 20 (white solid, 12.0 mg, yield 34.0%) was obtained, MS: 988.88 [M+Na] 2+ .

[0156] Step 7: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxo- Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,31,35-trioxy-33-(2-((((3R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-7,10,13,16,19,22,25,28octaoxa-4,32,36triazatetradecane-40 acid

[0157] Compound 20 (12.0 mg, 0.0061 mmol) was added with dichloromethane (2 mL) and hydrochloric acid ethyl acetate solution (1 ml, 4 M), and reacted at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 20 was complete. The solvent was removed by distillation under reduced pressure, and the product was separated and purified by preparative liquid phase separation (acetonitrile / water). Compound DL-4 (white solid, 4.0 mg, yield 34.3%) was prepared. MS: 1899.22 [M+H] + .

[0158] 1 H NMR(400MHz,DMSO-d6)δ8.12–7.98(m,3H),7.28–7.17(m,6H),7.14(m,2H),4.67(m,2H),4.62(d,J=8.9Hz,1H),4 .57(m,2H),4.51(m,2H),3.96(s,2H),3.58–3.44(m,5H),3.41(m,5H),3.22(m,6H),3.20–3.13(m,9H),3.07(s,3H ),3.00(m,4H),2.76(m,3H),2.63(m,2H),2.41(m,5H),2.27(m,4H),2.20(m,9H),1.74(m,6H),1.48(m,3H),1.40( d,J=10.9Hz,2H),1.35–1.28(m,3H),1.24(m,8H),1.04(d,J=6.7Hz,2H),1.00–0.80(m,27H),0.79–0.49(m,13H).

[0159] Example 5: Preparation of Compound DL-5

[0160]

[0161] Step 1: Synthesis of ethyl 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamide)-3-phenylpropanamide)ethoxy)L-alanine

[0162] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (98.7 mg, 0.232 mmol) and HATU (92.4 mg, 0.243 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, and then DIEA (110 μL, 0.663 mmol) and compound 9 (200 mg, 0.221 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 9 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and then separated and purified by silica gel column chromatography with 3% MeOH / DCM. Compound 10 (white solid, 210 mg, yield 72.4%) was prepared. MS: 628.56 [M-tBu] 2+ .

[0163] Step 2: Synthesis of tert-butyl (S)-4-amino-5-((((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate

[0164] Compound 10 (210 mg, 0.160 mmol) was added to N,N-dimethylformamide (5 mL) and piperidine (0.5 ml), and the reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 10 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50 mL*3 petroleum ether to remove impurities to obtain compound 11 (white solid, 160 mg, yield 91.8%). MS: 1090.59 [M+H] + .

[0165] Step 3: (3R,4R,7S,17S,20S,28R)-24-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-7-benzyl-20-(3-(tert-butyloxy)-3-oxopropyl)-3-((S)-1-((3R,4S,5S)-4-(((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido Synthesis of ((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,12,15-trioxy-6,9,18,21,27-pentaazanonane-29-oic acid)-(((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,17-dimethyl-5,8,16,19,22,26-hexaoxy-28-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,12,15-trioxy-6,9,18,21,27-pentaazanonane-29-oic acid)

[0166] Compound 3-Fmoc-aminoglutaric acid (108.6 mg, 0.294 mmol) and HATU (55.9 mg, 0.147 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (72.9 μL, 0.441 mmol) and compound 10 (160 mg, 0.147 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when the compound 10 in the reaction solution was less than 3%. The reaction solution was distilled under reduced pressure to remove the solvent and purified by preparative liquid separation (acetonitrile / water). Compound 17 (white solid, 125 mg, yield 59.1%) was prepared. MS: 693.14 [M-tBu+2H] 2+ .

[0167] Step 4: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14yl (9S,12 Synthesis of S)-9-(3-(tert-butoxy)-3-oxypropyl)-1-(9H-fluoro-9-12-methyl-12-methyl-3,7,10-trioxy-5-(2-oxo-oxy-oxy-oxy-oxy-oxy-oxy-oxy-propyl)((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)ethyl)-2-oxa-4,8,11-triazatridecanoic acid 13-acid ester

[0168] Compound 17 (60 mg, 0.042 mmol) and HATU (17.5 mg, 0.046 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (20.9 μL, 0.126 mmol) and compound 1-deoxynojirimycin (13.7 mg, 0.084 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 17, and the reaction was considered to be complete. The reaction liquid was distilled under reduced pressure to remove the solvent, and purified by preparative liquid separation (acetonitrile / water). Compound 21 (white solid, 35 mg, yield 53.0%) was prepared. MS: 792.50 [M+2H] 2+ / 2.

[0169] Step 5: Synthesis of tert-butyl (4S)-4-(3-amino-5-oxo-5-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)pentaamido)-5-((3R,4L,7S,17S)-7-benzyl-3-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate

[0170] Compound 21 (35 mg, 0.022 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 ml) and reacted at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 21 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50*3 mL of petroleum ether to remove impurities to obtain compound 22 (white solid, 15.0 mg, yield 50.0%). MS: 682.63 [M+2H] 2+ / 2.

[0171] Step 6: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-[(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazaazaalkane-14-yl (2S,5S )-5-(3-(tert-butoxy)-3-oxypropyl)-41-(2,5-dioxy-2,5-dihydro-1H-pyrrol-1-yl)-2-methyl)-2-methyl-9-(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)ethyl)-14,17,20,23,26,29,32,35-octaoxo-3,6,10,38-tetraazabenzene tetracarboxylate

[0172] The compound maleimide octaethylene glycol propionic acid (6.5 mg, 0.011 mmol) and HATU (4.6 mg, 0.012 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (5.5 μL, 0.033 mmol) and compound 22 (15.0 mg, 0.011 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 22, and the reaction was considered to be complete. The reaction liquid was distilled under reduced pressure to remove the solvent, and purified by preparative liquid phase separation (acetonitrile / water). The preparative freeze-dried compound 23 (white solid, 10.0 mg, yield 47.0%) was obtained, MS: 969.86 [M+2H] 2+ / 2.

[0173] Step 7: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadecane Synthesis of 1-(2,5-dioxodihydro-1H-pyrrolidin-1-yl)-3,31,31,31,31,35-trioxo-33-(2-oxo-2-((2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl)ethyl)-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetracan-40-oic acid

[0174] Compound 23 (10.0 mg, 0.0052 mmol) was added with dichloromethane (2 mL) and hydrochloric acid ethyl acetate solution (1 ml, 4 M), and reacted at room temperature for 1 h. LCMS monitored the complete reaction of the raw material compound 23. The solvent was removed by distillation under reduced pressure, and the product was separated and purified by preparative liquid phase separation (acetonitrile / water). Compound DL-5 (white solid, 4.0 mg, yield 41.2%) was prepared. MS: 1883.229 [M+H] + .

[0175] 1 H NMR(400MHz,D2O)δ8.39(s,1H),7.91(d,J=20.7Hz,1H),7.36–7.16(m,5H),6.82(s,2H ),4.63(m,4H),4.40–4.30(m,2H),4.29–4.19(m,3H),4.16(s,1H),4.05(s,2H),3.81( s,2H),3.78–3.72(m,5H),3.69(m,6H),3.64(m,14H),3.62(m,5H),3.57(m,2H),3.51( m,2H),3.45(d,J=7.1Hz,2H),3.39(s,1H),3.37(d,J=5.6Hz,1H),3.33(s,2H),3.29(s, 3H),3.27(d,J=4.9Hz,2H),3.24–3.16(m,3H),3.14(s,1H),3.11(s,2H),2.90(m,6H), 2.84–2.77(m,2H),2.68(s,3H),2.53(d,J=11.1Hz,2H),2.51–2.36(m,6H),2.28(m,4H ),2.17–1.92(m,4H),1.85(m,4H),1.73–1.47(m,4H),1.38(m,4H),1.35–1.21(m,2H), 1.15(d,J=6.7Hz,2H),1.06(m,3H),1.02–0.93(m,8H),0.90(m,4H),0.86–0.74(m,3H).

[0176] Example 6: Preparation of Compound DL-6

[0177]

[0178] Step 1: Synthesis of 2-(2-((S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)3-phenylpropionamido(ethoxy)ethyl(tert-butoxycarbonyl)-L-valine

[0179] Compound 1 (181 mg, 0.217 mmol) and compound Boc-valine (236 mg, 1.086 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature to dissolve, and then placed in an ice bath. DIEA (450 uL, 2.713 mmol), HOBT (205 mg, 1.519 mmol), and EDCI (262 mg, 1.367 mmol) were added in sequence at 0-5 °C. The reaction was carried out at 0-5 °C for 3 hours, and then at room temperature for 12 hours. LCMS showed that the reaction was completed when the compound 1 in the reaction solution was less than 3%. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in sequence. The organic phases were combined after two extractions, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The crude product was separated and purified by silica gel column chromatography using 10% MeOH / DCM. Compound 2 (white solid, 320 mg, yield 143%) was prepared. MS: 1033.38 [M+H] +

[0180] Step 2: Synthesis of ethyl 2-(2-((S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)3-phenylpropionamido(ethoxy)L-valine Compound 2 (320 mg, 0.31 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (5 mL) and HCl / 1,4-dioxane solution (2 ml, 4 M) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored the reaction of the raw material compound 2. After spin drying, compound 3 (white solid, 337 mg, yield 116.6%) was obtained. MS: 933.26 [M+H] +

[0181] Step 3: Synthesis of tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,18-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazanonan-17-yl)amino)-5-oxopentanoate

[0182] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (46 mg, 0.107 mmol) and HATU (49 mg, 0.107 mmol) were added to N,N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, then DIEA (71 uL, 0.428 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 3 (100 mg, 0.107 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction liquid contained less than 3% of compound 3, and the reaction was considered to be complete. The reaction liquid was evaporated to dryness under reduced pressure, and the crude product was separated and purified by silica gel column chromatography using MeOH / DCM. Compound 4 (white solid, 128 mg, yield 89%) was prepared. MS: 670.86 [M+2H] 2+ / 2

[0183] Step 4: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1)-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,18-dimethyl-5,8,16-trioxo-2,12,15-trioxo-6,9-diazanonadecan-17-yl)amino)-5-oxopentanoate

[0184] Compound 4 (128 mg, 0.096 mmol) was placed in a 25 mL single-mouth bottle, and N, N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 4 was complete. The reaction solution was evaporated under reduced pressure to dry the solvent, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 5 (white solid, 24 mg, yield 22.6%) was obtained. MS: 1118.48 [M+H] +

[0185] Step 5: Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-((S)-1-((3R,4S,5S))-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isopropyl-4-methyl-5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid

[0186] Compound 3-Boc-aminoglutaric acid (11 mg, 0.043 mmol) and HATU (20 mg, 0.052 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, then DIEA (28 uL, 0.172 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 5 (24 mg, 0.021 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 5 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 6 (white solid, 17 mg, yield 58.8%) was prepared. MS: 674.36 [M+2H] 2+ / 2

[0187] Step 6: Synthesis of (3R, 4R, 7S)-7-benzyl-3-((S)-1-((3R, 4S, 5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14-yl(18S, 21S)-18-(3-(tert-butoxy)-3-oxypropyl)-14-(tert-butoxycarbonyl)amino)-21-isopropyl-12,16,19-trioxy-2 5,8-trioxa-11,17,20-triazadocosa-22-oic acid

[0188] Compound methyl-triethylene glycol-amine (13 mg, 0.0096 mmol) and HATU (4.4 mg, 0.0115 mmol) were added to N,N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, then DIEA (6.4 uL, 0.0384 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 6 (3.2 mg, 0.0193 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 6 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 24 (white solid, 13 mg, yield 90.7%) was prepared. MS: 746.96 [M+2H] 2+ / 2

[0189] Step 7: Synthesis of (3R,4R,7S,17S,20S)-20-(14-amino-12-oxo-2,5,8-trioxa-11-azahexadecane-16-amino)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isopropyl-4-methyl-5,8,16,19-tetraoxy-2,12,15-trioxy-6,9,18-triazatrioxane-23-oic acid

[0190] Compound 24 (13 mg, 0.0072 mmol) was added with dichloromethane (2 mL) and hydrochloric acid / 1,4-dioxane solution (0.4 ml, 4 M), and reacted at room temperature for 0.5 h. LCMS monitored that the reaction of the raw material compound 24 was complete. After spin drying, compound 25 (white solid, 15 mg, yield 129.3%) was obtained. MS: 668.84 [M+2H] 2+ / 2

[0191] Step 8: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,18-dimethyl-5,8,16-trioxo-2,12,15-trioxo-6,9-diazanonane Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,31,35-trioxo-33-(12-oxo-2,8,8-trioxo-11-azatridecane-13-yl)-7,13,13,16,19,22,25,28-octaoxo-4,32,36-triazatetraoxane-40-carboxylic acid

[0192] The compound maleimide octaethylene glycol propionic acid (6.7 mg, 0.0112 mmol) and HATU (5.1 mg, 0.0134 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (7.4 uL, 0.0448 mmol) was added and stirred at room temperature for 10 minutes. Finally, compound 25 (15 mg, 0.0112 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 25 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by preparative liquid phase separation with acetonitrile / water. Freeze-dried to obtain compound DL-6 (white solid, 4 mg, yield 18.6%). MS: 1911.31 [M+H] +

[0193] 1 H NMR(400MHz,D2O)δ7.23(s,5H),6.79(s,2H),4.61(m,4H),4.55–4.38(m,3H),4.23(m,4H),4.02(s,2H),3.71(m,2H),3 .67(m,3H),3.61(m,15H),3.59(m,8H),3.56–3.50(m,4H),3.48(m,2H),3.42(m,2H),3.35(m,2H),3.30(s,5H),3.26(m, 3H),3.24(s,1H),3.23(s,2H),3.16(m,2H),3.12(s,1H),3.09(s,2H),2.92–2.74(m,3H),2.60(m,4H),2.50(m,3H),2.4 2(m,7H),2.32–2.07(m,5H),1.88–1.69(m,3H),1.28(m,4H),1.02(m,3H),0.94(m,7H),0.90–0.83(m,6H),0.79(m,5H).

[0194] Example 7: Preparation of Compound DL-7

[0195] Step 1: Synthesis of (S)-N-((3R,4S,5S)-1-((S)-2-((3R,4R,7S)-7-benzyl-14-hydroxy-4-methyl-5,8-dioxy-2,12-dioxy-6,9-diazatetradecane-3-yl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptane-4-yl)-2-(S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide

[0196] Compound 9 (260.0 mg, 0.288 mmol) and Na2CO3 (306.0 mg, 2.88 mmol) were added to methanol (3 mL) and stirred at room temperature for 2 hours. LCMS showed that the reaction was completed when the compound 9 in the reaction solution was less than 3%. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice, and the organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The preparative liquid phase was separated and purified with acetonitrile / water. Compound 1 (white solid, 202.0 mg, yield 84.3%) was prepared. MS: 834.56 [M+H] + .

[0197] Step 2: Synthesis of 2-(S)-2-((2R.3R)-3-(S)-1-((3R.4S.5S)-4-(S)-2-(2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)-3-phenylpropionamidoethoxy)ethyl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-leucine

[0198] Compound Fmoc-L-leucine (94.7 mg, 0.268 mmol) and HATU (101.9 mg, 0.0.268 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (121 μL, 0.729 mmol) and compound 1 (202 mg, 0.243 mmol) were added and stirred at room temperature for 10 hours. LCMS showed that the reaction was completed when the compound 1 in the reaction solution was less than 3%. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice, combined organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 26 (white solid, 283 mg, yield 100%) was prepared. MS: 585.32 [M+2H] 2+ / 2.

[0199] Step 3: Synthesis of 2-(2-(S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)-3-phenylpropionamido(ethoxy)ethyl L-leucine

[0200] Compound 26 (283 mg, 0.242 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 ml) and reacted at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 26 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50*3 mL of petroleum ether to remove impurities to obtain compound 27 (white solid, 281 mg, yield 123%). MS: 947.69 [M+H] + .

[0201] Step 4: tert-Butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3RS,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,19-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazabicycloalkane Synthesis of Fmoc-L-glutamic acid-5-tert-butyl ester (139.2 mg, 0.327 mmol) and HATU (124.4 mg, 0.327 mmol) were added to N,N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (148 μL, 0.891 mmol) and compound 27 (281 mg, 297 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 27 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 28 (white solid, 247 mg, yield 74.6%) was prepared. MS: 649.73 [M-tBu] 2+ .

[0202] Step 5: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,19-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazabicycloalkane-17-yl)amino)-5-oxopentanoate

[0203] Compound 28 (247 mg, 0.182 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 ml) and reacted at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 28 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50*3 mL of petroleum ether to remove impurities to obtain compound 29 (white solid, 237 mg, yield 115%). MS: 566.89 [M+2H] 2+ / 2.

[0204] Step 6: Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isobutyl-4-methyl 5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid

[0205] Compound 3-Boc-aminoglutaric acid (26.2 mg, 0.106 mmol) and HATU (40.3 mg, 0.106 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (52.5 μL, 0.318 mmol) and compound 29 (120 mg, 0.106 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 29 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 30 (white solid, 50 mg, yield 34.7%) was prepared. MS: 631.10 [M-Boc] 2+ .

[0206] Step 7: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazepan-14-yl(10S,13S)-10-(3-(tert-butoxy)-3-oxopropyl)-13-isobutyl-2,2-dimethyl-6-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,8,11-trioxo-3-oxo-5,9,12-triazatetradecanoate

[0207] Compound meglumine (25 mg, 0.0184 mmol) and HATU (7.7 mg, 0.0202 mmol) were added to N,N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (9.5 μL, 0.0552 mmol) and compound 30 (7.2 mg, 0.0368 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 30, which was considered to be the end of the reaction. The solvent was removed by distillation under reduced pressure, and acetonitrile / water was used for preparative liquid phase separation and purification. Compound 31 (white solid, 24 mg, yield 84.9%) was prepared. MS: 719.73 [M-Boc] 2+ .

[0208] Step 8: Synthesis of (3R,4R,7S,17S,20S)-20-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamide)-7-benzyl-3-(S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isobutyl-4-methyl 5,8,16,19-tetraoxo-2,12,15-trioxo-6,9,18-triazatriazole-23-oic acid

[0209] Compound 31 (24 mg, 0.0156 mmol) was added with dichloromethane (1.0 mL) and ethyl acetate solution of hydrochloric acid (0.5 ml, 4 M), and reacted at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 31 was complete. The solvent was removed by distillation under reduced pressure, and acetonitrile / water was used for preparative liquid phase separation and purification. Compound 32 (white solid, 21.5 mg, yield 100%) was prepared. MS: 691.63 [M+2H] 2+ / 2.

[0210] Step 9: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S,(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,19-dimethyl-5,8,16-trioxy-2,12,15-trioxy- Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25-28-octaoxo-4,32,36-triazatetrapentane-40-carboxylic acid

[0211] The compound maleimide octaethylene glycol propionic acid (9.3 mg, 0.0156 mmol) and HATU (6.0 mg, 0.0156 mmol) were added to N, N-dimethylformamide (1.5 mL), stirred at room temperature for 10 minutes, and then DIEA (8.0 μL, 0.0486 mmol) and compound 32 (21.5 mg, 0.0156 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 32, and the reaction was considered to be complete. The reaction liquid was distilled under reduced pressure to remove the solvent, and acetonitrile / water was used for preparative liquid phase separation and purification. The preparative freeze-dried compound DL-7 (white solid, 4.0 mg, yield 13.2%) was obtained, MS: 1957.34 [M+H] + .

[0212] 1H NMR(400MHz,D2O)δ7.30–7.13(m,5H),6.79(s,2H),4.60(d,J=9.2Hz,1H),4.48(s,1H),4.36(s,1H),4.29–4.14(m,3H),4.08– 3.86(m,3H),3.71(m,6H),3.67(m,5H),3.61(m,21H),3.60–3.55(m,8H),3.55–3.51(m,2H),3.48(m,3H),3.45–3.32(m,4H),3. 30(s,2H),3.25(m,7H),3.20–3.13(m,2H),3.10(m,3H),3.05(m,2H),2.92–2.79(m,8H),2.61(m,3H),2.55–2.32(m,9H),2.25( s,4H),1.97(s,3H),1.80(m,3H),1.59(m,6H),1.24(m,4H),1.12(s,1H),1.03(m,3H),0.95(m,10H),0.87(m,8H),0.78(s,6H).

[0213] Example 8: Preparation of Compound DL-8

[0214]

[0215] Step 1: Synthesis of (S)-N-((3R,4S,5S)-1-((S)-2-((3R,4R,7S)-7-benzyl-14-hydroxy-4-methyl-5,8-dioxy-2,12-dioxy-6,9-diazatetradecane-3-yl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptane-4-yl)-2-(S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide

[0216] Compound 9 (260.0 mg, 0.288 mmol) and Na2CO3 (306.0 mg, 2.88 mmol) were added to methanol (3 mL) and stirred at room temperature for 2 hours. LCMS showed that the reaction was completed when the compound 9 in the reaction solution was less than 3%. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice, and the organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The preparative liquid phase was separated and purified with acetonitrile / water. Compound 1 (white solid, 202.0 mg, yield 84.3%) was prepared. MS: 834.56 [M+H] + .

[0217] Step 2: Synthesis of 2-(S)-2-((2R.3R)-3-(S)-1-((3R.4S.5S)-4-(S)-2-(2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)-3-phenylpropionamidoethoxy)ethyl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-leucine

[0218] Compound Fmoc-L-leucine (94.7 mg, 0.268 mmol) and HATU (101.9 mg, 0.0.268 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (121 μL, 0.729 mmol) and compound 1 (202 mg, 0.243 mmol) were added and stirred at room temperature for 10 hours. LCMS showed that the reaction was completed when the compound 1 in the reaction solution was less than 3%. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice, combined organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 26 (white solid, 283 mg, yield 100%) was prepared. MS: 586.32 [M+H] + .

[0219] Step 3: Synthesis of 2-(2-(S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-ethoxy-2-methylpropionamido)-3-phenylpropionamido(ethoxy)ethyl L-leucine

[0220] Compound 26 (283 mg, 0.242 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 ml) and reacted at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 26 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50*3 mL of petroleum ether to remove impurities to obtain compound 27 (white solid, 281 mg, yield 123%). MS: 947.69 [M+H] + .

[0221] Step 4: Synthesis of tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3RS,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,19-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazabicycloalkane-17-yl)amino)-5-oxopentanoate

[0222] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (139.2 mg, 0.327 mmol) and HATU (124.4 mg, 0.327 mmol) were added to N,N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (148 μL, 0.891 mmol) and compound 27 (281 mg, 297 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 27 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 28 (white solid, 247 mg, yield 74.6%) was prepared. MS: 649.73 [M-tBu] 2+ / 2.

[0223] Step 5: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,19-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazabicycloalkane-17-yl)amino)-5-oxopentanoate

[0224] Compound 28 (247 mg, 0.182 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 ml) and reacted at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 28 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50*3 mL of petroleum ether to remove impurities to obtain compound 29 (white solid, 237 mg, yield 115%). MS: 1132.79 [M+H] + .

[0225] Step 6: Synthesis of (3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-24-((tert-butoxycarbonyl)amino)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isobutyl-4-methyl 5,8,16,19,22-pentaoxo-2,12,15-trioxo-6,9,18,21-tetraazahexacan-26-oic acid

[0226] Compound 3-Boc-aminoglutaric acid (26.2 mg, 0.106 mmol) and HATU (40.3 mg, 0.106 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (52.5 μL, 0.318 mmol) and compound 29 (120 mg, 0.106 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 29 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 30 (white solid, 50 mg, yield 34.7%) was prepared. MS: 631.10 [M-Boc] 2+ / 2.

[0227] Step 7: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14-yl(18S,21S)-18-(3-(tert-butoxy)-3-oxypropyl)-14-(tert-butoxycarbonyl)amino)-21-isobutyl-12,16,19-trioxy-2,58-trioxo-11,17,20-triazadocosapentaenoic acid

[0228] Compound methyl-triethylene glycol-amine (25 mg, 0.0184 mmol) and HATU (7.7 mg, 0.0202 mmol) were added to N,N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (9.5 μL, 0.0552 mmol) and compound 30 (6.0 mg, 0.0368 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 30, which was considered to be the end of the reaction. The solvent was removed by distillation under reduced pressure, and acetonitrile / water was used for preparative liquid phase separation and purification. Compound 33 (white solid, 17 mg, yield 61.4%) was prepared. MS: 703.82 [M-Boc] 2+ / 2.

[0229] Step 8: Synthesis of (3R,4R,7S,17S,20S)-20-(14-amino-12-oxo-2,5,8-trioxa-11-azahexadecane-16-amino)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-17-isobutyl-4-methyl 5,8,16,19-tetraoxy-2,12,15-trioxy-6,9,18-triazatrioxane-23-oic acid

[0230] Compound 33 (17 mg, 0.0113 mmol) was added with dichloromethane (1.0 mL) and ethyl acetate solution of hydrochloric acid (0.5 ml, 4 M), and reacted at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 33 was complete. The solvent was removed by distillation under reduced pressure, and acetonitrile / water was used for preparative liquid phase separation and purification. Compound 34 (white solid, 15.3 mg, yield 100%) was prepared. MS: 675.79 [M+2H] 2+ / 2.

[0231] Step 9: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,19-dimethyl-5,8,16-trioxo-2,12,15-trioxo-6,9-diazatriazine Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,31,35-trioxo-33-(12-oxo-2,8,8-trioxo-11-azatridecane-13-yl)-7,13,13,16,19,22,25,28-octaoxo-4,36-triazatetradecane-40-oic acid

[0232] The compound maleimide octaethylene glycol propionic acid (6.7 mg, 0.0113 mmol) and HATU (6.0 mg, 0.0113 mmol) were added to N, N-dimethylformamide (1.5 mL), stirred at room temperature for 10 minutes, and then DIEA (6.0 μL, 0.0339 mmol) and compound 34 (15.3 mg, 0.0113 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 34, and the reaction was considered to be complete. The reaction liquid was distilled under reduced pressure to remove the solvent, and acetonitrile / water was used for preparative liquid phase separation and purification. The preparative freeze-dried compound DL-8 (white solid, 3.5 mg, yield 16.1%) was obtained. MS: 1925.33 [M+H] + .

[0233] 1 H NMR(400MHz,D2O)δ8.35(s,2H),7.22(s,1H),7.22(s,5H),6.79(s,2H),4.61(s,1H),4.49(m,1H),4.43–4.33(m,1H), 4.22(m,3H),4.02(s,1H),3.71(m,4H),3.66(m,3H),3.65–3.56(m,31H),3.56–3.51(m,5H),3.48(m,3H),3.30(m,8H) ,3.28–3.20(m,8H),3.20–2.99(m,7H),2.87(m,7H),2.64(m,2H),2.41(m,9H),2.32–2.15(m,1H),2.10–1.88(m,1H), 1.85–1.70(m,1H),1.61(m,5H),1.27(s,3H),1.11(s,1H),1.03(m,3H),0.95(m,10H),0.87(m,7H),0.82–0.72(m,6H).

[0234] Example 9: Preparation of Compound DL-9

[0235]

[0236] Step 1: Synthesis of tert-butyl (S)-13-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-12-oxo-2,5,8-trioxa-11-azahexadecane-16-oic acid

[0237] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (130.2 mg, 0.306 mmol) and HATU (116.5 mg, 0.306 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (152 μL, 0.306 mmol) and compound methyl-triethylene glycol-amine (50.0 mg, 0.306 mmol) were added and stirred at room temperature for 10 hours. LCMS monitoring of the reaction was completed, the reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice, combined organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification were performed with acetonitrile / water. Compound 35 (white solid, 168.1 mg, yield 96.2%) was prepared. MS: 572.59 [M+H] + .

[0238] Step 2: Synthesis of (S)-13-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-12-oxo-2,5,8-trioxa-11-azahexadecane-16-oic acid

[0239] Compound 35 (168.1 mg, 0.295 mmol) was added with dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 ml), and the reaction was carried out at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 35 was complete. The solvent was removed by distillation under reduced pressure, and acetonitrile / water was used for preparative liquid phase separation and purification. Compound 36 (white solid, 170.3 mg, yield 112.4%) was prepared. MS: 516.63 [M+H] + .

[0240] Step 3: Synthesis of (13S)-13-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-18-(3-(tert-butyloxy)-3-oxopropyl)-12,16-dioxo-2,5,8-trioxa-11,17-diazanonan-19-oic acid

[0241] Compound L-glutamic acid-5-tert-butyl ester (170.3 mg, 0.331 mmol) and HATU (125.8 mg, 0.331 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (164 μL, 0.993 mmol) and compound 36 (67.3 mg, 0.331 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 36 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 37 (white solid, 142.7 mg, yield 61.6%) was prepared. MS: 692.79 [M+H] + .

[0242] Step 4: Synthesis of (13S)-13-amino-18-(3-(tert-butoxy)-3-oxopropyl)-12,16-dioxo-2,5,8-trioxa-11,17-diazahexadecane-19-oic acid

[0243] Compound 37 (142.7 mg, 0.204 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 ml) and reacted at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 37 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50*3 mL of petroleum ether to remove impurities to obtain compound 38 (white solid, 65.5 mg, yield 67.3%). MS: 479.42 [M+H] + .

[0244] Step 5: Synthesis of (7S)-2-(3-(tert-butoxy)-3-oxopropyl)-39-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-7-((2-(2-methoxyethoxy)ethoxyethyl)carbamoyl)-4,9,37-trioxy-12,15,18,21,24,27,30,33-octaoxy-3,8,36-triazacyclotricarboxylic acid

[0245] The compound maleimide octaethylene glycol propionic acid (81.3 mg, 0.137 mmol) and HATU (52.2 mg, 0.137 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (68 μL, 0.412 mmol) and compound 38 (65.5 g, 0.137 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when the compound 38 in the reaction solution was less than 3%. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 39 was prepared as a white solid, 32.8 mg, yield 22.7%). MS: 1054.20 [M+H] + .

[0246] Step 6: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazazepan-14-yl (2S,10S)-5-(3-(tert-butyloxy)-3- Synthesis of 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-4-(2-(2-(2-(2-methoxyethoxy)ethoxyethyl)carbamoyl)-2-methyl-4,7,12,40-tetraoxo-15,18,21,24,27,30,33,36-octaoxy-3,6,11,39-tetraazatetracarboxylic acid

[0247] Compound 39 (16.4 mg, 0.0156 mmol) and HATU (5.9 mg, 0.0156 mmol) were added to N,N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (8 μL, 0.0468 mmol) and compound 9 (14.1 mg, 0.0368 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 39, and the reaction was considered to be complete. The solvent was removed by distillation under reduced pressure, and acetonitrile / water was used for preparative liquid phase separation and purification. Compound 40 (white solid, 14.3 mg, yield 47.3%) was prepared. MS: 970.52 [M+2H] 2+ / 2.

[0248] Step 7: (33S)-38-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadecanoyl Synthesis of 1-(2,5-dioxy-2,5-dihydro-1H-pyrrolidin-1-yl)-3,3-((2-(2-(-2-methoxyethoxy)ethoxyethyl)carbamoyl)-3,31,36-trioxo-7,10,13,16,19,22,25-28-octaoxy-4,32,37-triazinetetracarboxylic acid

[0249] Compound 40 (14.3 mg, 0.0074 mmol) was added with dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 ml), and the reaction was carried out at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 40 was complete. The solvent was removed by distillation under reduced pressure, and acetonitrile / water was used for preparative liquid phase separation and purification. Compound DL-9 (white solid, 7.6 mg, yield 154.7%) was prepared. MS: 1883.26 [M+H] + .

[0250] 1 H NMR(400MHz,D2O)δ7.33–7.26(m,1H),7.26–7.19(m,5H),7.19–7.12(m,1H),6.79(s,2H),4.68(s,2H),4.66(s,1H),4.65– 4.55(m,3H),4.34(m,2H),4.28(m,2H),4.22(m,3H),4.18(m,2H),3.81–3.65(m,12H),3.60(m,49H),3.57–3.51(m,10H),3. 49(m,4H),3.37–3.32(m,5H),3.30(m,9H),3.28–3.21(m,10H),3.20–3.05(m,8H),2.96–2.75(m,11H),2.59–2.47(m,5H),2 .47–2.34(m,9H),2.34–2.15(m,6H),1.57(m,4H),1.35(m,8H),1.03(m,5H),0.99–0.90(m,14H),0.88(m,6H),0.78(m,5H).

[0251] Example 10: Preparation of Compound DL-10

[0252]

[0253] Step 1: Synthesis of ethyl 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamide)-3-phenylpropanamide)ethoxy)L-alanine

[0254] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (50.0 mg, 0.0553 mmol) and HATU (21.0 mg, 0.0553 mmol) were added to N,N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (27 μL, 0.1659 mmol) and compound 9 (23.5 mg, 0.0053 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 9 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice, combined organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification were performed with acetonitrile / water. Compound 10 (white solid, 75.2 mg, yield 103.7%) was prepared. MS: 628.65 [M-tBu] 2+ .

[0255] Step 2: Synthesis of tert-butyl (S)-4-amino-5-((((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate

[0256] Compound 10 (75.2 mg, 0.0573 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 ml), and the reaction was carried out at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 3 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50*3 mL of petroleum ether to remove impurities to obtain compound 11 (white solid, 60.1 mg, yield 96.2%). MS: 545.30 [M+2H] 2+ / 2.

[0257] Step 3: (3R,4R,7S,17S,20S,28R)-24-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-7-benzyl-20-(3-(tert-butyloxy)-3-oxopropyl)-3-((S)-1-((3R,4S,5S)-4-(((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido Synthesis of ((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,12,15-trioxy-6,9,18,21,27-pentaazanonane-29-oic acid)-(((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,17-dimethyl-5,8,16,19,22,26-hexaoxy-28-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-2,12,15-trioxy-6,9,18,21,27-pentaazanonane-29-oic acid)

[0258] Compound 3-Fmoc-aminoglutaric acid (20.3 mg, 0.0551 mmol) and HATU (380.23 mg, 0.0551 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (27 μL, 0.1652 mmol) and compound 11 (60.1 mg, 0.0551 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 11 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 17 (white solid, 38.6 mg, yield 48.6%) was prepared. MS: 731.69 [M+Na] 2+ .

[0259] Step 4: Synthesis of (3R,4R,7S,17S,20S)-24-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-3-((S)-1-((3R,4S,5S)-4-(S)-2-(((S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19,22-pentaoxy-2,12,15-trioxy-6,9,18,21-tetraazahexadecane-26-octanoic acid

[0260] Compound 17 (5.2 mg, 0.0268 mmol) and HATU (10.2 mg, 0.0268 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (13 μL, 0.0804 mmol) and compound D-aminoglucosic acid (38.6 mg, 0.0268 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 17 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 41 (white solid, 12.0 mg, yield 27.7%) was prepared. MS: 810.12 [M+2H] 2+ / 2.

[0261] Step 5: Synthesis of (3R,4R,7S,17S,20S,28R)-24-amino-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-3-((S)-1-((3R,4S,5S)-4-((S,2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19,22,26-hexaoxy-28-((1R,2S,3R)-1,2,4-tetrahydroxybutyl)-2,2 12,15-trioxa-6,9,18,21,27-pentaazanonane-29-oic acid

[0262] Compound 41 (12.0 mg, 0.0074 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 ml) and reacted at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 41 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50*3 mL of petroleum ether to remove impurities to obtain compound 42 (white solid, 10.1 mg, yield 97.6%). MS: 698.56 [M+2H] 2+ / 2.

[0263] Step 6: (2R)-6-((3R,4R,7S,17S,20S)-7-benzyl-20-(3-(tert-butoxy)-3-oxopropyl)-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19,22-pentaoxo-2,12, Synthesis of 15-trioxo-6,9,18,21-tetraazatriazol-23-yl)-38-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-4,836-trioxy-2-(((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-11,14,17,20,23,26,26,29,32-octaoxo-3,7,35-triazaoctacarbonic acid

[0264] The compound maleimide octaethylene glycol propionic acid (4.3 mg, 0.0072 mmol) and HATU (2.8 mg, 0.0072 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (4 μL, 0.0217 mmol) and compound 42 (10.1 mg, 0.0072 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when the compound 42 in the reaction solution was less than 3%. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 43 (white solid, 10.2 mg, yield 71.5%) was prepared. MS: 985.76 [M+2H] 2+ / 2.

[0265] Step 8: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S-2-((S,(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9- Synthesis of 3,3-(2-(((1R,2R,3S,4R)-1-carboxy-2,3,4,5-tetrahydroxypentyl)amino)-2-oxoethyl)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetracan-40-oic acid

[0266] Compound 43 (10.2 mg, 0.0052 mmol) was added with dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 ml), and the reaction was carried out at room temperature for 30 mins. LCMS monitored that the reaction of the raw material compound 43 was complete. The solvent was removed by distillation under reduced pressure, and acetonitrile / water was used for preparative liquid phase separation and purification. Compound DL-10 (white solid, 4.5 mg, yield 45.4%) was prepared. MS: 1915.23 [M+H] + .

[0267] 1 H NMR(400MHz,D2O)δ7.22(s,5H),6.79(d,J=1.0Hz,2H),4.61(m,3H),4.33(s,1H),4.22( m,3H),4.06(s,1H),3.78–3.64(m,9H),3.62(m,21H),3.46–3.34(m,4H),3.30(s,2H),3. 28–3.20(m,6H),3.20–3.04(m,5H),2.87(m,6H),2.58–2.30(m,11H),1.76(d,J=6.9Hz,3 H),1.35(m,4H),1.27(s,3H),1.06–0.99(m,3H),0.95(m,8H),0.87(m,4H),0.77(s,3H).

[0268] Example 11: Preparation of Compound DL-11

[0269]

[0270] Step 1: Synthesis of tert-butyl (3R, 4R, 7S, 17S, 20S)-20-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-7-benzyl-3-((S)-1-((3R, 4S, 5S)-4-((S, 2-(dimethylamino)-3-methylbutanamido)-N, 3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19-tetraoxo-2,12-dioxy-6,9,15,18-tetraazatriazole-23-acid salt

[0271] Compound 44 (11 mg, 0.0122 mmol), compound Fmoc-L-glutamic acid-5-tert-butyl ester (5.2 mg, 0.0122 mmol), and HATU (5.6 mg, 0.0146 mmol) were added to N,N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (8 uL, 0.0488 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 1 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 45 (white solid, 13 mg, yield 81%) was prepared. MS: 656.34 [M+2H] 2+ / 2

[0272] Step 2: Synthesis of tert-butyl (3R, 4R, 7S, 17S, 20S)-20-amino-7-benzyl-3-((S)-1-((3R, 4S, 5S)-4-((S)-2-((S, (S)-2-(dimethylamino)-3-methylbutanamido)-N, 3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19-tetraoxo-2,12-dioxo-6,9,15,18-tetraazatriazol-23-oic acid

[0273] Compound 45 (13 mg, 0.010 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 45 was complete. The reaction solution was evaporated under reduced pressure to dry the solvent, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 46 (white solid, 9 mg, yield 83%) was obtained. MS: 1089.44 [M+H] +

[0274] Step 3: Synthesis of 3-((tert-butoxycarbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoic acid

[0275] Compound 3-Boc-aminoglutaric acid (253 mg, 1.025 mmol), compound meglumine (100 mg, 0.512 mmol), and HATU (390 mg, 1.025 mmol) were added to N, N-dimethylformamide (10 mL), stirred at room temperature for 10 minutes, and then DIEA (338 uL, 2.048 mmol) was added and stirred at room temperature for 3 hours. The reaction was monitored by LCMS. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 47 (colorless oil, 627 mg, yield 288%) was prepared. MS: 425.45 [M+H] +

[0276] Step 4: Synthesis of tert-butyl (3R, 4R, 7S, 17S, 20S)-7-benzyl-20-(3-((tert-butoxycarbonyl)amino)-5-(methyl((2S, 3R, 4L, 5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamide)-3-((S)-1-((3R, 4S, 5S)-4-((S(S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19-tetraoxo-2,12-dioxo-6,9,15,18-tetraazatriazole-23-acid salt

[0277] Compound 46 (9 mg, 0.008 mmol), compound 47 (4 mg, 0.008 mmol), and HATU (4.2 mg, 0.011 mmol) were added to N,N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (6 uL, 0.0368 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction liquid contained less than 3% of compound 46, and the reaction was considered to be complete. The reaction liquid was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 48 (white solid, 13 mg, yield 94%) was prepared. MS: 748.44 [M+2H] 2+ / 2

[0278] Step 5: Synthesis of (3R,4R,7S,17S,20S)-20-(3-amino-5-(methyl((2S,3R,7R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamido)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16,19-tetraoxo-2,12-dioxy-6,9,15 18-tetraazatriazole-23-octanoic acid

[0279] Compound 48 (13 mg, 0.009 mmol) was placed in a 10 mL single-mouth bottle, and dichloromethane (2 mL) and HCl / 1,4-dioxane solution (1 ml, 4 M) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 48 was complete. After being dried by rotation, the crude product compound 49 (white solid, 15 mg, yield 129%) was obtained. MS: 670.32 [M+2H] 2+ / 2

[0280] Step 6: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12-dioxy-6,9,15-triazaoctadec-17-yl)carbamoyl Synthesis of 1-(2,5-dioxy-2,5-dihydro-1H-pyrrol-1-yl)-33-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,31,31,35-trioxy-7,10,13,16,19,22,25,28-octaoxy-4,32,3,6-triazatetracarboxylic acid

[0281] Compound 49 (15 mg, 0.011 mmol), maleimide octaethylene glycol propionic acid (5.2 mg, 0.009 mmol), and HATU (4 mg, 0.01 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (6 uL, 0.035 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 49 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound DL-11 (white solid, 3 mg, yield 14%) was prepared. MS: 1914.27 [M+H] +

[0282] 1 H NMR(400MHz,D2O)δ7.37–7.13(m,5H),6.78(m,2H),4.65–4.46(m,1H),4.30–4.12(m,1H),4.04–3.90(m,1H) ,3.72(m,6H),3.60(m,50H),3.53–3.40(m,10H),3.37–3.28(m,6H),3.28–3.21(m,8H),3.20–2.98(m,8H),2 .91–2.76(m,10H),2.62(m,2H),2.43(m,10H),2.30–2.11(m,2H),2.01(m,1H),1.74(m,1H),1.66–1.42(m,1 H),1.30(m,3H),1.22(m,3H),1.11(m,1H),1.07–0.98(m,2H),0.98–0.90(m,10H),0.86(m,6H),0.78(m,5H).

[0283] Example 12: Preparation of Compound DL-12

[0284]

[0285] Step 1: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradec-14-yl (S)-2-((tert-butoxycarbonyl)amino)-2-cyclopropyl acetate

[0286] Compound 1 (30 mg, 0.036 mmol), compound Boc-L-cyclopropylglycine (8 mg, 0.036 mmol), and HATU (17 mg, 0.043 mmol) were added to N,N-dimethylformamide (4 mL), stirred at room temperature for 10 minutes, and then DIEA (24 uL, 0.144 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 1 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 50 (white solid, 36 mg, yield 97%) was prepared. MS: 1031.36 [M+H] +

[0287] Step 2: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaalkane-14-yl (S)-2-amino-2-cyclopropyl acetate

[0288] Compound 50 (36 mg, 0.035 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (2 mL) and HCl / 1,4-dioxane solution (1 ml, 4 M) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 3 was complete. After being spin-dried, the crude product compound 51 (white solid, 81 mg, yield 248%) was obtained. MS: 931.24 [M+H] +

[0289] Step 3: tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S,17S)-7-benzyl-17-cyclopropyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-(((S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-dihydro- Synthesis of 5-oxopentanoate (azoheptane-17-yl)amino)-5-oxopentanoate Compound 51 (81 mg, 0.087 mmol), compound Fmoc-L-glutamic acid-5-tert-butyl ester (37 mg, 0.087 mmol), and HATU (40 mg, 0.104 mmol) were added to N,N-dimethylformamide (4 mL) and stirred at room temperature for 10 minutes. Then DIEA (56 uL, 0.348 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction liquid contained less than 3% of compound 51, and the reaction was considered to be complete. The reaction liquid was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 52 (white solid, 27 mg, yield 23%) was prepared. MS: 669.86 [M+2H] 2+ / 2

[0290] Step 4: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S,17S)-7-benzyl-17-cyclopropyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazaheptadecan-17-yl)amino)-5-oxopentanoate

[0291] Compound 52 (27 mg, 0.02 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 52 was complete. The reaction solution was evaporated under reduced pressure to dry the solvent, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 53 (white solid, 24 mg, yield 106%) was obtained. MS: 558.74 [M+2H] 2+ / 2

[0292] Step 5: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazepan-14-yl(10S,13S)-10-(3-(tert-butoxy)-3-oxopropyl)-13-cyclopropyl-2,2-dimethyl-6-(2-(methyl((2S,3R,4R,5R)-2,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,8,11-trioxa-5,12-triazaazepane

[0293] Compound 47 (9 mg, 0.0.022 mmol) and HATU (10 mg, 0.026 mmol) were added to N,N-dimethylformamide (4 mL), stirred at room temperature for 10 minutes, and then DIEA (11 uL, 0.086 mmol) and compound 53 (24 mg, 0.022 mmol) were added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 53 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 54 (white solid, 22 mg, yield 66%) was prepared. MS: 761.95 [M+2H] 2+ / 2

[0294] Step 6: Synthesis of (3R,4R,7S,17S,20S)-20-(3-amino-5-(methyl((2S,3R,7R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamide)-7-benzyl-17-cyclopropyl-3-((S)-1-((3R,4S,5S)-4-((S,2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16,19-tetraoxo-2,12,15-trioxa-6,9,18-triazatriazole-23-oic acid

[0295] Compound 54 (22 mg, 0.014 mmol) was placed in a 10 mL single-mouth bottle, and dichloromethane (2 mL) and trifluoroacetic acid (1 ml) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 54 was complete. After being spin-dried, the crude product compound 55 (white solid, 36 mg, yield 182%) was obtained. MS: 683.84 [M+2H] 2+ / 2

[0296] Step 7: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-17-cyclopropyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8,16-trioxy-2,12,15-trioxy- Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25-28-octaoxo-4,32,36-triazatetraenoic acid

[0297] The compound maleimide octaethylene glycol propionic acid (15 mg, 0.026 mmol) and HATU (12 mg, 0.031 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (17 uL, 0.104 mmol) and compound 55 (36 mg, 0.026 mmol) were added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 55 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness, and the crude product was purified by preparative liquid separation using acetonitrile / water. Freeze-dried to obtain compound DL-12 (white solid, 2 mg, yield 4%). MS: 1941.3 [M+H]+

[0298] 1 H NMR (400MHz, DMSO-d6) δ8.01(s,1H),7.86(m,1H),7.68(m,1H),7.45–7.33(m,2H),7.33–7.10(m,5H),7.00(s,2H),4.67(s,3H),4.52( m,2H),4.34(m,3H),4.18(m,1H),4.12(m,2H),3.97(m,2H),3.77(m,3H),3.65–3.54(m,10H),3.49(m,32H),3.44–3.36(m,10H),3.24– 3.18(m,5H),3.15(m,3H),3.07(m,1H),3.00(m,4H),2.80(m,1H),2.76–2.66(m,2H),2.58–2.52(m,3H),2.33(m,3H),2.24(m,7H),1.7 4(m,3H),1.62(m,2H),1.43(m,3H),1.21(m,3H),1.06(m,3H),1.00–0.81(m,15H),0.75(m,5H),0.51(s,2H),0.38(s,1H),0.30(s,1H).

[0299] Example 13: Preparation of Compound DL-13

[0300]

[0301] Step 1: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazapyridin-14-yl 1-(((benzyloxy)carbonyl)amino)cyclopropane-1-carboxylate

[0302] Compound 1 (30 mg, 0.036 mmol), compound 1-Cbz-aminocyclopropanecarboxylic acid (8.5 mg, 0.036 mmol), and HATU (16 mg, 0.043 mmol) were added to N,N-dimethylformamide (4 mL), stirred at room temperature for 10 minutes, and then DIEA (24 uL, 0.144 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 1 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 56 (white solid, 34 mg, yield 90%) was prepared. MS: 1051.35 [M+H] +

[0303] Step 2: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazaazaalkane-14-yl-1-aminocyclopropanecarboxylate

[0304] Compound 56 (34 mg, 0.032 mmol) was placed in a 25 mL single-mouth bottle, methanol (3 mL) and Pd / C (15 mg) were added, and the air in the reaction bottle was replaced three times with a full hydrogen balloon under stirring. The reaction was carried out at room temperature for 3 hours. LCMS monitored that the reaction of the raw material compound 56 was complete. After filtration and spin drying, the crude product compound 57 (white solid, 30 mg, yield 101%) was obtained. MS: 917.22 [M+H] +

[0305] Step 3: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazacyclohexan-14-yl-1-(((S((9H-fluoro-9-methoxy)carbonyl)amino)-5-(tert-butoxy)-5-oxopentanamido)cyclopropane-1-carboxylate

[0306] Compound 57 (30 mg, 0.033 mmol), compound Fmoc-L-glutamic acid-5-tert-butyl ester (14 mg, 0.033 mmol), and HATU (15 mg, 0.04 mmol) were added to N,N-dimethylformamide (4 mL), stirred at room temperature for 10 minutes, and then DIEA (22 uL, 0.132 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 57 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 58 (white solid, 28 mg, yield 64%) was prepared. MS: 662.84 [M+2H] 2+ / 2

[0307] Step 4: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradec-14-yl 1-((S)-2-amino-5-(tert-butoxy)-5-oxopentanamido)cyclopropane-1-carboxylate

[0308] Compound 58 (28 mg, 0.021 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was allowed to proceed at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 6 was complete. The reaction solution was spin-dried to obtain the crude product compound 59 (colorless oil, 35 mg, yield 151%). MS: 1102.44 [M+H] +

[0309] Step 5: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazacan-14-yl 1-((2S)-5-(tert-butoxy)-2-(3-(tert-butoxycarbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanamido)-5-oxopentanamido)cyclopropane-1-carboxylate

[0310] Compound 47 (13 mg, 0.032 mmol) and HATU (15 mg, 0.038 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then compound 59 (35 mg, 0.032 mmol) and DIEA (22 uL, 0.128 mmol) were added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when compound 59 was less than 3% in the reaction solution. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 60 (white solid, 25 mg, yield 43.6%) was prepared. MS: 854.94 [M+2H] 2+ / 2

[0311] Step 6: Synthesis of (4S)-4-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoyl)-5-((1-((10S,13R,14R)-10-benzyl-14-((S)-1-((3R,4S,5S)-4-(S)-2-((S(2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-13-methyl-9,12-dioxy-2,5,15-trioxa-8,11-diazadecanoyl)cyclopropyl)amino)-5-oxopentanoic acid

[0312] Compound 60 (25 mg, 0.017 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (2 mL) and HCl / 1,4-dioxane solution (1 ml, 4 M) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 60 was complete. After being dried by rotation, the crude product compound 61 (white solid, 23 mg, yield 102%) was obtained. MS: 676.82 [M+2H] 2+ / 2

[0313] Step 7: (37S)-37-((1-((10S,13R,14R)-10-benzyl-14-((S)-1-((3R,4S,5S)-4-(S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-13-methyl-9,12-dioxy-2,5,15-trioxa-8,11-diazo Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetracan-40-oic acid

[0314] Take compound maleimido octaethylene glycol propionic acid (5 mg, 0.007 mmol) and compound 61 (9 mg, 0.007 mmol) and add them to N, N-dimethylformamide (3 mL), stir at room temperature for 10 minutes, then add DIEA (5 uL, 0.027 mmol) and stir at room temperature for 3 hours. LCMS shows that the reaction is completed when compound 61 is less than 3% in the reaction solution. The reaction solution is evaporated to dryness under reduced pressure, and the crude product is purified by preparative liquid separation with acetonitrile / water. Compound DL-13 (white solid, 1 mg, yield 7%) is prepared. MS: 1927.27 [M+H] +

[0315] 1 H NMR(400MHz,D2O)δ7.31–7.16(m,5H),6.79(s,2H),4.49(m,1H),4.04(m,2H),3.77–3 .46(m,56H),3.46–3.35(m,5H),3.34–3.20(m,12H),3.14(m,2H),3.08(m,6H),2.84(m ,8H),2.63(m,2H),2.43(m,7H),2.21(m,2H),1.98(m,1H),1.76(m,1H),1.51(m,2H), 1.24(m,1H),1.12(m,3H),1.06–0.98(m,2H),0.94(m,11H),0.86(m,6H),0.78(m,4H).

[0316] Example 14: Preparation of Compound DL-14

[0317]

[0318] Step 1: Synthesis of 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoic acid

[0319] Compound 3-Fmoc-aminoglutaric acid (100.1 mg, 0.271 mmol) and HATU (103.0 mg, 0.271 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (134 μL, 0.813 mmol) and compound meglumine (52.9 mg, 0.271 mmol) were added and stirred at room temperature for 1 hour. LCMS monitoring of the reaction was completed, the reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice, combined organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification were performed using acetonitrile / water. Compound 62 (white solid, 148.1 mg, yield 100%) was prepared. MS: 548.68 [M+H] + .

[0320] Step 2: (2S)-2-(3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoic acid

[0321] Compound L-glutamic acid-5-tert-butyl ester (148.1 mg, 0.271 mmol) and HATU (103.0 mg, 0.271 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (134 μL, 0.813 mmol) and compound 62 (55.1 mg, 0.271 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 62 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice, and the organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The preparative liquid phase was separated and purified with acetonitrile / water. Compound 63 (white solid, 166.6 mg, yield 84.0%) was prepared. MS: 733.20 [M+H] + .

[0322] Step 3: Synthesis of (2S)-2-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoic acid)-5-(tert-butoxy)-5-oxopentanoic acid

[0323] Compound 63 (166.6 mg, 0.228 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 ml), and the reaction was carried out at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 5 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50*3 mL of petroleum ether to remove impurities to obtain compound 64 (white solid, 116.1 mg, yield 100.1%). MS: 511.62 [M+H] + .

[0324] Step 4: Synthesis of (2S)-2-(3-(tert-butoxy)-3-oxopropyl)-38-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-6-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,8,36-trioxo-11,14,17,20,23,26,29,32-octaoxo-3,7,35-triazaoctacotrienoic acid Maleimidooctaethylene glycol propionic acid (45.0 mg, 0.0759 mmol) and HATU (28.9 mg, 0.0759 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (38 μL, 0.228 mmol) and compound 64 (38.7 mg, 0.0759 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 64, which was considered to be the end of the reaction. The reaction liquid was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 65 (white solid, 40.0 mg, yield 48.6%) was prepared. MS: 543.28 [M+2H] 2+ / 2.

[0325] Step 5: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14-yl (2S,5S)-2-benzyl-5-(3-(tert-butyloxy)-3-oxopropyl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14-yl Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-9-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,7,11,11,39-tetraoxo-14,17,20,23,26,29,33,35octaoxo-3,6,10,38-tetraazatetraoctanoate

[0326] Compound 65 (15.0 mg, 0.0138 mmol) and HATU (5.3 mg, 0.0138 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (7 μL, 0.0415 mmol) and compound 66 (13.6 mg, 0.0138 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 65 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 67 (white solid, 8.5 mg, yield 30.0%) was prepared. MS: 1024.46 [M+2H] 2+ / 2.

[0327] Step 6: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14-yl (2S,5S)-2-benzyl-5-(3-(tert-butyloxy)-3-oxopropyl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14-yl Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-9-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,7,11,11,39-tetraoxo-14,17,20,23,26,29,33,35octaoxo-3,6,10,38-tetraazatetraoctanoate

[0328] Compound 67 (10.2 mg, 0.0052 mmol) was added with dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 ml), and the reaction was carried out at room temperature for 30 mins. LCMS monitored that the reaction of the raw material compound 67 was complete. The solvent was removed by distillation under reduced pressure, and acetonitrile / water was used for preparative liquid phase separation and purification. Compound DL-14 (white solid, 0.48 mg, yield 5.8%) was prepared. MS: 1991.36 [M+H] + .

[0329] 1 H NMR(400MHz,D2O)δ7.36–7.05(m,13H),4.29(s,2H),4.20(s,3H),4.01(s,4H),3.70(m,7H),3.66–3.52(m,29H ),3.48(m,4H),3.33(m,4H),3.29(s,2H),3.24(m,7H),3.16(m,3H),3.10(s,2H),3.07(s,2H),3.05–3.00(m,2H ),2.87(m,10H),2.57(m,6H),2.42(m,10H),2.32–2.10(m,7H),1.75(m,5H),1.67–1.45(m,6H),1.31(m,8H),1. 11(d,J=6.8Hz,2H),1.04(d,J=6.7Hz,2H),1.00(d,J=6.7Hz,1H),0.98–0.89(m,9H),0.87(m,5H),0.78(m,5H).

[0330] Example 15: Preparation of Compound DL-15

[0331]

[0332] Step 1: Synthesis of 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoic acid

[0333] Compound 3-Fmoc-aminoglutaric acid (100.1 mg, 0.271 mmol) and HATU (103.0 mg, 0.271 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (134 μL, 0.813 mmol) and compound meglumine (52.9 mg, 0.271 mmol) were added and stirred at room temperature for 1 hour. The reaction was monitored by LCMS. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice, and the organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The preparative liquid phase was separated and purified with acetonitrile / water. Compound 62 (white solid, 148.1 mg, yield 100%) was prepared. MS: 548.68 [M+H] + .

[0334] Step 2: Synthesis of (2S)-2-(3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoamide)-5-(tert-butoxy)-5-oxopentanoic acid

[0335] Compound 62 (148.1 mg, 0.271 mmol) and HATU (103.0 mg, 0.271 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (134 μL, 0.813 mmol) and compound L-glutamic acid-5-tert-butyl ester (55.1 mg, 0.271 mmol) were added and stirred at room temperature for 1 hour. The reaction was monitored by LCMS. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice, and the organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The preparative liquid phase was separated and purified with acetonitrile / water. Compound 63 (white solid, 166.6 mg, yield 84.0%) was prepared. MS: 733.20 [M+H] + .

[0336] Step 3: Synthesis of (2S)-2-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoic acid)-5-(tert-butoxy)-5-oxopentanoic acid

[0337] Compound 63 (166.6 mg, 0.228 mmol) was added to N,N-dimethylformamide (2 mL) and piperidine (0.2 ml), and the reaction was carried out at room temperature for 15 mins. LCMS monitored that the reaction of the raw material compound 5 was complete. The reaction solution was distilled under reduced pressure to remove the solvent, and then repeatedly washed with 50*3 mL of petroleum ether to remove impurities to obtain compound 64 (white solid, 116.1 mg, yield 100.1%). MS: 511.62 [M+H] + .

[0338] Step 4: Synthesis of (2S)-2-(3-(tert-butoxy)-3-oxopropyl)-38-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-6-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,8,36-trioxo-11,14,17,20,23,26,29,32-octaoxo-3,7,35-triazaoctacotrienoic acid Maleimidooctaethylene glycol propionic acid (45.0 mg, 0.0759 mmol) and HATU (28.9 mg, 0.0759 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (38 μL, 0.228 mmol) and compound 64 (38.7 mg, 0.0759 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction liquid contained less than 3% of compound 64, which was considered to be the end of the reaction. The reaction liquid was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 65 (white solid, 40.0 mg, yield 48.6%) was prepared. MS: 543.28 [M+2H] 2+ .

[0339] Step 5: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazatetradecane-14-yl (2S,5S)-5-(3-(tert-butoxy)-3-oxopropyl)-2-(tert-butoxymethyl)-41-( Synthesis of 2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-9-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,7,11,11,3,39-tetraoxo-14,17,20,23,26,29,32,35-octaoxo-3,35-octaoxy-6,,10,38-tetraazabenzene tetracarboxylate

[0340] Compound 65 (15.0 mg, 0.0138 mmol) and HATU (5.3 mg, 0.0138 mmol) were added to N, N-dimethylformamide (2 mL), stirred at room temperature for 10 minutes, and then DIEA (7 μL, 0.0415 mmol) and compound 68 (13.5 mg, 0.0138 mmol) were added and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed when compound 68 was less than 3% in the reaction solution. The reaction solution was diluted 2 times and washed with water (15 mL) and saturated brine (15 mL) in turn, extracted twice and combined the organic phases, dried over anhydrous sodium sulfate, evaporated the solvent under reduced pressure, and prepared liquid phase separation and purification was performed with acetonitrile / water. Compound 69 (white solid, 14.0 mg, yield 49.5%) was prepared. MS: 1022.48 [M+2H] 2+ .

[0341] Step 6: (37S)-37-(((3R,4R,7S,17S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-18-hydroxy-4-methyl-5,8,16-trioxy-2,12,15-trioxo-6,9-diazaoctadec-17-yl)amino Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-33-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,31,35-trioxy-7,10,13,16,19,22,25,28-octaoxy-4,32,3,6-triazatetracan-40-oic acid

[0342] Compound 69 (14.0 mg, 0.0069 mmol) was added with dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 ml), and the reaction was carried out at room temperature for 30 mins. LCMS monitored that the reaction of the raw material compound 69 was complete. The solvent was removed by distillation under reduced pressure, and acetonitrile / water was used for preparative liquid phase separation and purification. Compound DL-15 (white solid, 0.48 mg, yield 5.8%) was prepared. MS: 1931.26 [M+H] + .

[0343] 1 H NMR(400MHz,D2O)δ7.30–7.13(m,5H),6.79(s,2H),4.60(m,1H),4.48(s,1H),4.36(s,1H),4.29–4.14(m,3H),4.08–3.86(m,3 H),3.71(m,6H),3.67(m,5H),3.61(m,21H),3.60–3.55(m,8H),3.55–3.51(m,2H),3.48(m,3H),3.45–3.32(m,4H),3.30(s,2H) ,3.25(m,7H),3.20–3.13(m,2H),3.10(m,3H),3.05(d,J=4.7Hz,2H),2.92–2.79(m,8H),2.61(m,3H),2.55–2.32(m,9H),2.25( s,4H),1.97(s,3H),1.80(m,3H),1.59(s,6H),1.24(m,4H),1.12(s,1H),1.03(m,3H),0.95(m,10H),0.87(m,8H),0.78(s,6H).

[0344] Example 16: Preparation of Compound DL-16

[0345]

[0346] Step 1: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazapyridin-14-yl-2-((tert-butoxycarbonyl)amino)-2-methylpropanoate

[0347] Compound N-tert-butyloxycarbonyl-2-methylalanine (12 mg, 0.06 mmol) and HATU (27 mg, 0.07 mmol) were added to N,N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, then DIEA (40 uL, 0.24 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 1 (50 mg, 0.06 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when compound 1 was less than 3% in the reaction solution. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 70 (white solid, 44 mg, yield 72%) was prepared. MS: 1019.35 [M+H] +

[0348] Step 2: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diaza ...

[0349] Compound 70 (44 mg, 0.04 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (3 mL) and HCl / 1,4-dioxane solution (1 ml, 4 M) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 70 was complete. After being spin-dried, the crude product compound 71 (white solid, 43 mg, yield 110%) was obtained. MS: 919.23 [M+H] +

[0350] Step 3: Synthesis of tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16-trioxy-2,12,15-trioxa-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate

[0351] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (20 mg, 0.047 mmol) and HATU (22 mg, 0.056 mmol) were added to N,N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, then DIEA (24 uL, 0.188 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 71 (43 mg, 0.047 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when compound 71 was less than 3% in the reaction solution. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 72 (white solid, 41 mg, yield 66%) was prepared. MS: 663.85 [M+2H] 2+ / 2

[0352] Step 4: Synthesis of tert-butyl (S)-4-amino-5-(((3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16-trioxo-2,12,15-trioxo-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate

[0353] Compound 72 (41 mg, 0.031 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 72 was complete. The reaction solution was spin-dried, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 73 (white solid, 31 mg, yield 91%) was obtained. MS: 1104.45 [M+H] +

[0354] Step 5: Synthesis of (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazaazepan-14-yl(9S)-9-(3-(tert-butoxy)-3-oxopropyl)-1-(9H-fluoro-9-yl)-12,12-dimethyl-5-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,7,10-trioxy-4,11-triazatridecane-13-oic acid

[0355] Compound 62 (23 mg, 0.042 mmol) and HATU (19 mg, 0.05 mmol) were added to N, N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then compound 73 (31 mg, 0.028 mmol) and DIEA (18 uL, 0.112 mmol) were added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 73 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 74 (white solid, 31 mg, yield 67.8%) was prepared. MS: 817.0 [M+2H] 2+ / 2

[0356] Step 6: Synthesis of tert-butyl (4S)-4-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoyl)-5-(((3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16-trioxy-2,12,15-trioxa-6,9-diazaoctadec-17-yl)amino)-5-oxopentanoate

[0357] Compound 74 (31 mg, 0.019 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 74 was complete. The reaction solution was spin-dried, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 75 (white solid, 23 mg, yield 86%) was obtained. MS: 705.88 [M+2H] 2+ / 2

[0358] Step 7: (3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-4-methyl-5,8-dioxo-2,12-dioxo-6,9-diazepin-14-yl (5S)-5-(3-(tert-butyloxy)- Synthesis of 3-oxopropyl)-41-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-2,2-dimethyl-9-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,7,11,39-tetraoxo-14,17,20,23,26,29,32,32,35-octaoxo-3,6,10,38-tetraazabenzene tetracarboxylate

[0359] Compound 75 (23 mg, 0.016 mmol), maleimide octaethylene glycol propionic acid (12 mg, 0.016 mmol), and HATU (7.3 mg, 0.019 mmol) were added to N,N-dimethylformamide (3 mL) and stirred evenly. Then DIEA (8 uL, 0.064 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction liquid contained less than 3% of compound 75, and the reaction was considered to be complete. The reaction liquid was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 76 (white solid, 17 mg, yield 53.5%) was prepared. MS: 993.2 [M+2H] 2+ / 2

[0360] Step 8: (37S)-37-(((3R,4R,7S)-7-benzyl-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-4,17-dimethyl-5,8,16-trioxy-2,12,15-trioxy-6,9-diazo Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrolidin-1-yl)-3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetracan-40-oic acid

[0361] Compound 76 (17 mg, 0.009 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (3 mL) and trifluoroacetic acid (1 ml) were added. The reaction was allowed to proceed at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 12 was complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound DL-16 (white solid, 8.9 mg, yield 53.9%) was obtained. MS: 1929.29 [M+H] +

[0362] 1 H NMR(400MHz,D2O)δ7.34–7.11(m,5H),6.79(s,2H),4.64–4.55(m,4H),4. 56–4.45(m,2H),4.27–4.12(m,4H),4.05–3.99(m,1H),3.98–3.87(m,2H), 3.80–3.67(m,5H),3.68–3.52(m,29H),3.52–3.46(m,3H),3.45–3.38(m, 2H),3.39–3.32(m,2H),3.30(s,2H),3.28–3.21(m,6H),3.20–3.00(m,8H) ,2.95–2.75(m,9H),2.73–2.56(m,4H),2.55–2.33(m,10H),2.32–2.14(m ,4H),2.09–1.92(m,4H),1.81(d,J=42.7Hz,5H),1.65–1.45(m,4H),1.40( s,6H),1.32–1.19(m,3H),1.14–1.08(m,2H),1.05(d,J=6.7Hz,2H),1.03– 0.98(m,2H),0.99–0.90(m,9H),0.90–0.82(m,5H),0.78(t,J=7.3Hz,4H).

[0363] Example 17: Preparation of Compound DL-17

[0364]

[0365] Step 1: Synthesis of 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S()-2-(S)-2-(dimethylamino)-3-methylbutyramido)-N,3-dimethylbutyramido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methyl-2-methylpropionamido)-3-phenylpropionamidoethoxy)ethyl N2-((((9H-fluoren-9-yl)methoxy)carbonyl)-N6-(tert-butoxycarbonyl)-L-lysine salt

[0366] Compound N-Fmoc-N'-Boc--L-lysine (21 mg, 0.045 mmol) and HATU (20 mg, 0.053 mmol) were added to N,N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, then DIEA (30 uL, 0.18 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 1 (40 mg, 0.045 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when compound 1 was less than 3% in the reaction solution. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 76 (white solid, 46 mg, yield 75.4%) was prepared. MS: 678.37 [M+2H] 2+ / 2

[0367] Step 2: 2-(2-((S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-((S)-2-(S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methyl-2-methylpropanamido)-3-phenylpropanamidoethoxy)ethyl N6-(tert-butoxycarbonyl)-L-lysine

[0368] Compound 76 (46 mg, 0.034 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 76 was complete. The reaction solution was spin-dried, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 77 (white solid, 36 mg, yield 93.5%) was obtained. MS: 567.26 [M+2H] 2+ / 2

[0369] Step 3: 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamide)-N,3-methylbutanamide)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-methoxy-2-methylpropionamido)-3-phenylpropionamido)ethoxy)ethyl N 2-(3-(((((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentananoyl)-N6-(tert-butoxycarbonyl)-1-lysyl-alanine

[0370] Compound 62 (26 mg, 0.048 mmol) and HATU (24 mg, 0.063 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, then DIEA (21 uL, 0.126 mmol) was added and stirred at room temperature for 10 minutes, and finally compound 77 (36 mg, 0.032 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 77 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 78 (white solid, 26 mg, yield 48.9%) was prepared. MS: 831.52 [M+2H] 2+ / 2

[0371] Step 4: 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methyl-2-methylpropanamido)-3-phenylpropanamidoethoxy)ethyl N2-(3-amino-5-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-5-oxopentanoyl)-N6-(tert-butoxycarbonyl)-L-lysyl-L-alanine

[0372] Compound 78 (26 mg, 0.016 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 78 was complete. The reaction solution was spin-dried, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 79 (white solid, 7.6 mg, yield 33%) was obtained. MS: 720.4 [M+2H] 2+ / 2

[0373] Step 5: 2-(2-((S)-2-((2R,3R)-3-(S)-1-((3R,4S,5S)-4-(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanamido)ethoxy)ethyl N6-(tert-butoxycarbonyl) Synthesis of -N2-(1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-33-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31-dioxy-7,10,13,16,19,22,25,28-octaoxy-4,32-diazapentaazacyclopentane-35-yl)-L-lysine-alanine

[0374] The compound maleimide octaethylene glycol propionic acid (3.76 mg, 0.006 mmol) and HATU (3 mg, 0.008 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, and then DIEA (3.5 uL, 0.021 mmol) was added and stirred at room temperature for 10 minutes. Finally, compound 79 (7.6 mg, 0.005 mmol) was added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 79 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 80 (white solid, 5 mg, yield 49.7%) was prepared. MS: 1007.72 [M+2H] 2+ / 2

[0375] Step 6: 2-(2-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanamido)ethoxy)ethyl(1 Synthesis of -(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-33-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31-dioxy-7,10,13,16,19,22,25,28-octaoxy-4,32-diazatricyclo-35-oxy)-L-lysyl-L-alanine

[0376] Compound 80 (5 mg, 0.0025 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (3 mL) and hydrochloric acid / 1,4-dioxane solution (1 ml, 4 M) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 80 was complete. After being dried by rotation, the crude product compound DL-17 (white solid, 2 mg, yield 41.8%) was obtained. MS: 1914.32 [M+H] +

[0377] 1 H NMR(400MHz,D2O)δ7.32–7.16(m,5H),6.79(s,2H),4.66–4.46(m,2H),4.37–4.15(m,2H),4.14–3.82(m,1 H),3.78–3.65(m,9H),3.64–3.51(m,45H),3.51–3.34(m,9H),3.32–3.20(m,11H),3.16–3.03(m,6H),2.94 –2.80(m,10H),2.69–2.60(m,2H),2.51–2.35(m,8H),2.32–1.94(m,2H),1.85–1.68(m,2H),1.66–1.42(m ,6H),1.41–1.20(m,7H),1.14–0.98(m,3H),0.99–0.90(m,11H),0.90–0.82(m,6H),0.78(t,J=7.3Hz,5H).

[0378] Example 18: Preparation of Compound DL-18

[0379]

[0380] Step 1: Synthesis of 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl(tert-butoxycarbonyl)valine salt

[0381] Compound Boc-valine (53 mg, 0.242 mmol) and HATU (92 mg, 0.0.242 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 20 minutes, and then DIEA (134 uL, 0.808 mmol) and compound 80 (100 mg, 0.202 mmol) were added and stirred at room temperature for 24 hours. LCMS showed that there was a small amount of compound 80 remaining in the reaction solution, and the reaction was considered to be complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 81 (white solid, 167 mg, yield 119.3%) was obtained. MS: 693.74 [M+H] +

[0382] Step 2: Synthesis of 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl valine

[0383] Compound 81 (167 mg, 0.241 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (5 mL) and hydrochloric acid ethyl acetate solution (1 ml, 4 M) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 81 was complete. After spin drying, a yellow solid was obtained. Compound 82 (yellow solid, 142 mg, yield 92%) was obtained. MS: 593.62 [M+H] +

[0384] Step 3: Synthesis of tert-butyl (4S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoate

[0385] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (102 mg, 0.239 mmol) and HATU (110 mg, 0.287 mmol) were added to dichloromethane (10 mL), stirred at room temperature for 20 minutes, and then DIEA (158 uL, 0.956 mmol) and compound 82 (142 mg, 0.239 mmol) were added and stirred at room temperature for 5 hours. LCMS showed that there was a small amount of compound 82 remaining in the reaction solution, and the reaction was completed. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by silica gel column chromatography using 3% MeOH / DCM. Compound 83 (white solid, 72 mg, yield 30%) was obtained. MS: 1001.09 [M+H] +

[0386] Step 4: Synthesis of tert-butyl (4S)-4-amino-5-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoate

[0387] Compound 83 (72 mg, 0.072 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 83 was complete. After being spin-dried, the crude product was purified by preparative liquid phase separation to obtain compound 84 (white solid, 34 mg, yield 60.7%). MS: 778.85 [M+H] +

[0388] Step 5: Synthesis of 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((2S)-5-(tert-butoxy)-1-((1-(2-((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)aminoamino)-1,5-dioxopentan-2-yl)amino)-5-oxopentanic acid

[0389] Compound 3-Fmoc-aminoglutaric acid (19.4 mg, 0.0524 mmol) and HATU (24 mg, 0.063 mmol) were added to N, N-dimethylformamide (4 mL), stirred at room temperature for 20 minutes, and then DIEA (35 uL, 0.21 mmol) and compound 84 (34 mg, 0.0437 mmol) were added and stirred at room temperature for 4 hours. LCMS showed that the reaction was completed when the compound 84 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation. Compound 85 (white solid, 21 mg, yield 42.9%) was obtained. MS: 1130.21 [M+H] +

[0390] Step 6: Synthesis of 3-amino-5-(((2S)-5-(tert-butoxy)-1-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)aminoamino)-1,5-dioxopentan-2-ylamino)-5-oxopentanic acid

[0391] Compound 85 (21 mg, 0.019 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 85 was complete. After being spin-dried, the crude product was separated and purified by preparative liquid phase separation to obtain compound 86 (white solid, 16 mg, yield 92.9%). MS: 907.96 [M+H] +

[0392] Step 7: (8S,17S,18R,19R,20R)-8-(3-(tert-butoxy)-3-oxopropyl)-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[generation]pyrano[3',4':6,7]naza[1,2-b]quinolin-1-yl) Synthesis of 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azabenzenetricarboxylate (amino)-17,18,19,20,21-pentahydroxy-5-isopropyl-15-methyl-1,4,7,10,14-pentaoxo-3-oxo-6,9,15-triazacyclohexane-12-yl 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azabenzenetricarboxylate

[0393] Compound maleimidooctaethylene glycol propionic acid (12.4 mg, 0.021 mmol) and HATU (9.6 mg, 0.025 mmol) were added to N,N-dimethylformamide (3 mL), stirred at room temperature for 20 minutes, and then DIEA (14 uL, 0.084 mmol) and compound 86 (16 mg, 0.018 mmol) were added and stirred at room temperature for 3 hours. LCMS showed that the reaction solution contained less than 3% of compound 86, and the reaction was considered to be complete. Compound 87 was obtained and was directly used for the next step without purification.

[0394] At this time, HATU (9.6 mg, 0.025 mmol) was added, stirred at room temperature for 5 minutes, and then DIEA (7 uL, 0.041 mmol) and compound meglumine (6.1 mg, 0.031 mmol) were added and stirred at room temperature for 3 hours. LCMS showed that the reaction liquid contained less than 3% of compound 86, which was considered to be the end of the reaction. The reaction liquid was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation. Compound 88 (white solid, 11 mg, yield 36.8%) was obtained. MS: 742.28 [M+2H] 2+ / 2

[0395] Step 8: (37S)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-37-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline Synthesis of 3,3-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxo-4,32,36-triazatetracarboxylic acid

[0396] Compound 88 (11 mg, 0.007 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (5 mL) and hydrochloric acid ethyl acetate solution (1 ml, 4 M) were added. The reaction was allowed to proceed at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 88 was complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by HPLC. Compound DL-18 (white solid, 10 mg, yield 89.3%) was obtained. MS: 1603.68 [M+H] +

[0397] 1H NMR (400MHz, DMSO-d6) δ8.02(s,1H),7.87(d,J=10.9Hz,1H),7.38(s,1H),7.07(s,1H),5.83(s,1H),5.68–5.60(m,1H),5.50(s,2H),5.31(m 2H),4.63(m,2H),4.45–4.25(m,3H),4.17–4.05(m,1H),3.87–3.78(m, 1H),3.70–3.13(m,42H),2.47(s,3H),2.42–2.17(m,9H),1.97–1.85(m ,3H),1.81–1.67(m,2H),1.61–1.50(m,2H),1.45–1.39(m,2H),1.39–1 .32(m,5H),1.30(s,6H),1.27–1.21(m,3H),1.00(m,5H),0.93(m,4H).

[0398] Example 19: Preparation of Compound DL-19

[0399] Step 1: Synthesis of 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl(tert-butoxycarbonyl)valine salt

[0400] Compound Boc-valine (53 mg, 0.242 mmol) and HATU (92 mg, 0.0.242 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 20 minutes, and then DIEA (134 uL, 0.808 mmol) and compound 80 (100 mg, 0.202 mmol) were added and stirred at room temperature for 24 hours. LCMS showed that there was a trace amount of compound 80 remaining in the reaction solution, and the reaction was considered to be complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 81 (white solid, 167 mg, yield 119.3%) was obtained. MS: 693.74 [M+H] +

[0401] Step 2: Synthesis of 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl valine

[0402] Compound 81 (167 mg, 0.241 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (5 mL) and hydrochloric acid ethyl acetate solution (1 ml, 4 M) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 81 was complete. After spin drying, a yellow solid compound 82 (yellow solid, 142 mg, yield 93%) was obtained. MS: 593.62 [M+H] +

[0403] Step 3: Synthesis of tert-butyl (4S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoate

[0404] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (102 mg, 0.239 mmol) and HATU (110 mg, 0.287 mmol) were added to dichloromethane (10 mL), stirred at room temperature for 20 minutes, and then DIEA (158 uL, 0.956 mmol) and compound 82 (142 mg, 0.239 mmol) were added and stirred at room temperature for 5 hours. LCMS showed that there was a small amount of compound 82 remaining in the reaction solution, and the impurity peak was large, and the reaction was completed. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by silica gel column chromatography using 3% MeOH / DCM. Compound 83 (white solid, 72 mg, yield 30%) was obtained. MS: 1001.09 [M+H] +

[0405] Step 4: Synthesis of tert-butyl (4S)-4-amino-5-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoate

[0406] Compound 83 (72 mg, 0.072 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 83 was complete. After being spin-dried, the crude product was purified by preparative liquid phase separation to obtain compound 84 (white solid, 34 mg, yield 60.7%). MS: 778.85 [M+H] +

[0407] Step 5: Synthesis of 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((2S)-5-(tert-butoxy)-1-((1-(2-((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)aminoamino)-1,5-dioxopentan-2-yl)amino)-5-oxopentanic acid

[0408] Compound 3-Fmoc-aminoglutaric acid (19.4 mg, 0.0524 mmol) and HATU (24 mg, 0.063 mmol) were added to N, N-dimethylformamide (4 mL), stirred at room temperature for 20 minutes, and then DIEA (35 uL, 0.21 mmol) and compound 84 (34 mg, 0.0437 mmol) were added and stirred at room temperature for 4 hours. LCMS showed that the reaction was completed when the compound 84 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation. Compound 85 (white solid, 21 mg, yield 42.9%) was obtained. MS: 1130.21 [M+H] +

[0409] Step 6: Synthesis of 3-amino-5-(((2S)-5-(tert-butoxy)-1-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)aminoamino)-1,5-dioxopentan-2-ylamino)-5-oxopentanic acid

[0410] Compound 85 (21 mg, 0.019 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 85 was complete. After being spin-dried, the crude product was separated and purified by preparative liquid phase separation to obtain compound 86 (white solid, 16 mg, yield 92.9%). MS: 907.96 [M+H] +

[0411] Step 7: (18S)-18-(3-(tert-butoxy)-3-oxopropyl)-25-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino) Synthesis of 1-(2,5-dioxo-2,25-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azatrioxan-31-ol-21-isopropyl-12,16,19,22,25-pentaoxo-2,5,8,23-tetraoxa-11,17,20-triazapentacarbonyl-14-yl)-1-(2,5-dioxo-2,25-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azatrioxan-31-ol

[0412] Compound maleimidooctaethylene glycol propionic acid (6.5 mg, 0.011 mmol) and HATU (5.0 mg, 0.013 mmol) were added to N,N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (7.3 uL, 0.044 mmol) and compound 86 (10 mg, 0.011 mmol) were added and stirred at room temperature for 3 hours. LCMS showed that the reaction solution contained less than 3% of compound 86, and the reaction was considered to be complete. Compound 87 was obtained and was directly used for the next step without purification.

[0413] At this time, HATU (5.0 mg, 0.013 mmol) was added, stirred at room temperature for 5 minutes, and then DIEA (4 uL, 0.024 mmol) and compound methyl-triethylene glycol-amine (2.7 mg, 0.017 mmol) were added and stirred at room temperature for 3 hours. LCMS showed that the reaction liquid contained less than 3% of compound 87, which was considered to be the end of the reaction. The reaction liquid was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation. Compound 89 (white solid, 10 mg, yield 55.6%) was obtained. MS: 814.88 [M+2H] 2+ / 2

[0414] Step 8: (37S)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-37-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,13,15-hexahydro-1H,12H-benzo[3',4':6,7]indolizine[1,2-b]quinoline Synthesis of (1,2-(4-(1-(2-((1-((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((

[0415] Compound 89 (10 mg, 0.006 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (1 mL) and HCl / 1,4-dioxane solution (1 ml, 4 M) were added. The reaction was allowed to proceed at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 14 was complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by HPLC. Compound DL-19 (white solid, 2 mg, yield 21.2%) was obtained. MS: 1571.66 [M+H] +

[0416] 1 H NMR(400MHz,D2O)δ7.24(m,2H),6.76(m,2H),5.54(s,2H),5.42(m,1H),5.28(d,J=16.3Hz,1H),4.98(d, J=18.9Hz,1H),4.77(s,3H),4.40–4.27(m,1H),4.11(s,1H),3.88(s,1H),3.67(m,2H),3.64–3.59(m,10 H),3.59(m,4H),3.57(m,6H),3.56–3.53(m,8H),3.51(s,3H),3.46(m,3H),3.27(m,3H),3.22(m,4H),3. 03(m,5H),2.35(m,10H),2.29(s,1H),2.22–2.01(m,9H),1.85(m,3H),1.64(m,4H),0.88–0.69(m,10H).

[0417] Example 20: Preparation of Compound DL-20

[0418]

[0419] Step 1: Synthesis of 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl(tert-butoxycarbonyl)valine salt

[0420] Compound Boc-valine (53 mg, 0.242 mmol) and HATU (92 mg, 0.0.242 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 20 minutes, and then DIEA (134 uL, 0.808 mmol) and compound 80 (100 mg, 0.202 mmol) were added and stirred at room temperature for 24 hours. LCMS showed that there was a small amount of compound 80 remaining in the reaction solution, and the reaction was considered to be complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by preparative liquid phase separation using acetonitrile / water. Compound 81 (white solid, 167 mg, yield 119.3%) was obtained. MS: 693.74 [M+H] +

[0421] Step 2: Synthesis of 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl valine

[0422] Compound 81 (167 mg, 0.241 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (5 mL) and hydrochloric acid ethyl acetate solution (1 ml, 4 M) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 81 was complete. After spin drying, a yellow solid was obtained. Compound 82 (yellow solid, 142 mg, yield 93%) was obtained. MS: 593.62 [M+H] +

[0423] Step 4: Synthesis of tert-butyl (4S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoate

[0424] Compound Fmoc-L-glutamic acid-5-tert-butyl ester (102 mg, 0.239 mmol) and HATU (110 mg, 0.287 mmol) were added to dichloromethane (10 mL), stirred at room temperature for 20 minutes, and then DIEA (158 uL, 0.956 mmol) and compound 82 (142 mg, 0.239 mmol) were added and stirred at room temperature for 5 hours. LCMS showed that there was a small amount of compound 82 remaining in the reaction solution, and the impurity peak was large, and the reaction was completed. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by silica gel column chromatography using 3% MeOH / DCM. Compound 83 (white solid, 72 mg, yield 30%) was obtained. MS: 1001.09 [M+H] +

[0425] Step 5: Synthesis of tert-butyl (4S)-4-amino-5-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoate

[0426] Compound 83 (72 mg, 0.072 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 83 was complete. After being spin-dried, the crude product was purified by preparative liquid phase separation to obtain compound 84 (white solid, 34 mg, yield 60.7%). MS: 778.85 [M+H] +

[0427] Step 6: Synthesis of 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(((2S)-5-(tert-butoxy)-1-((1-(2-((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)aminoamino)-1,5-dioxopentan-2-yl)amino)-5-oxopentanic acid

[0428] Compound 3-Fmoc-aminoglutaric acid (19.4 mg, 0.0524 mmol) and HATU (24 mg, 0.063 mmol) were added to N, N-dimethylformamide (4 mL), stirred at room temperature for 20 minutes, and then DIEA (35 uL, 0.21 mmol) and compound 84 (34 mg, 0.0437 mmol) were added and stirred at room temperature for 4 hours. LCMS showed that the reaction was completed when the compound 84 in the reaction solution was less than 3%. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation. Compound 85 (white solid, 21 mg, yield 42.9%) was obtained. MS: 1130.21 [M+H] +

[0429] Step 7: Synthesis of 3-amino-5-(((2S)-5-(tert-butoxy)-1-((1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)-3-methyl-1-oxobutan-2-yl)aminoamino)-1,5-dioxopentan-2-ylamino)-5-oxopentanic acid

[0430] Compound 85 (21 mg, 0.019 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (5 mL) and piperidine (0.5 ml) were added. The reaction was carried out at room temperature for 10 min. LCMS monitored that the reaction of the raw material compound 85 was complete. After being spin-dried, the crude product was separated and purified by preparative liquid phase separation to obtain compound 86 (white solid, 16 mg, yield 92.9%). MS: 907.96 [M+H] +

[0431] Step 8: 2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethyl (2R,5S)-5-(3-(tert-butyloxy)-3-oxopropyl)-41-(2,5- Synthesis of dioxo-2,5-dihydro-1H-pyrrol-1-yl)-2-isopropyl-4,7,11,39-tetraoxo-9-(2-oxo-2-(((3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)ethyl)-14,17,20,23,26,29,32,35-octaoxa-3,6,10,38-tetraazabenzene tetracarboxylate

[0432] Compound maleimidooctaethylene glycol propionic acid (7 mg, 0.011 mmol) and HATU (5.0 mg, 0.013 mmol) were added to N,N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then DIEA (7.3 uL, 0.044 mmol) and compound 86 (10 mg, 0.011 mmol) were added and stirred at room temperature for 3 hours. LCMS showed that the reaction solution contained less than 3% of compound 86, and the reaction was considered to be complete. Compound 87 was obtained and was directly used for the next step without purification.

[0433] At this time, HATU (5.0 mg, 0.013 mmol) was added, stirred at room temperature for 5 minutes, and then DIEA (4 uL, 0.024 mmol) and compound D-glucosamine hydrochloride (5 mg, 0.022 mmol) were added and stirred at room temperature for 3 hours. LCMS showed that the reaction was completed when the compound 87 in the reaction solution was less than 3%. The reaction solution was evaporated under reduced pressure to dry the solvent, and the crude product was purified by preparative liquid separation. Compound 90 (white solid, 7 mg, yield 38.9%) was obtained. MS: 822.37 [M+2H] 2+ / 2

[0434] Step 9: (37S)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-37-(((R)-1-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-3,3,9,10,13,15-hexahydro-1H,12H)-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino Synthesis of (2-oxo-2-(((3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)ethyl)-7,10,13,16,19,22,25,28-octaoxa-4,32,36-triazatetracan-40-oic acid)-2-(((3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)ethyl ...3,31,35-trioxy-33-(2-oxo-2-(((3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)ethyl)-7,10,13,16,19,22,25,28-octaoxa-4,32,36-triazatetracan-40-oic acid)

[0435] Compound 90 (7 mg, 0.004 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (1 mL) and HCl / 1,4-dioxane solution (1 ml, 4 M) were added. The reaction was allowed to proceed at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 90 was complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was separated and purified by HPLC. Compound DL-20 (white solid, 1 mg, yield 14.8%) was obtained. MS: 1587.64 [M+H] +

[0436] 1H NMR(400MHz,D2O)δ8.37(s,1H),7.86(s,1H),7.26(s,2H),6.76(d,J=1.9Hz,2H),5.54(s,2H),5.43(d,J=1 6.5Hz,2H),5.29(m,2H),5.14–4.92(m,4H),4.76(s,3H),4.38(m,2H),4.11(m,2H),3.97–3.64(m,6H),3.6 4–3.49(m,16H),3.46(s,3H),3.35(s,2H),3.22(m,2H),3.04(s,3H),2.94(s,1H),2.78(s,1H),2.37(m,7H ),2.17(s,3H),2.05(m,4H),1.93–1.76(m,3H),1.76–1.52(m,3H),1.46(m,1H),1.24(m,4H),0.82(m,10H).

[0437] Example 21: Preparation of Compound DL-21

[0438]

[0439] Step 1: Synthesis of 2-(2-(tert-butoxy)-2-oxoethoxy)ethyl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-valine

[0440] Compound Fmoc-valine (97 mg, 0.286 mmol) and HATU (130 mg, 0.342 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, and then DIEA (94 uL, 0.568 mmol) and compound 91 (50 mg, 0.284 mmol) were added and stirred at room temperature for 24 hours. LCMS showed that a small amount of compound 91 remained in the reaction solution, and the reaction was considered to be complete. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 92 (white solid, 110 mg, yield 77.8%) was obtained. MS: 498.59 [M+H] +.

[0441] Step 2: Synthesis of (S)-1-(9H-fluoren-9-yl)-5-isopropyl-3,6-dioxo-2,7,10-trioxo-4-azadodecane-12-oic acid

[0442] Compound 92 (110 mg, 0.221 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (5 mL) and hydrochloric acid / 1,4-dioxane solution (2 ml, 4 M) were added. The reaction was carried out at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 92 was complete. After being spin-dried, a yellow solid was obtained. Compound 93 (yellow solid, 70 mg, yield 71.7%) was obtained. MS: 442.48 [M+H]+.

[0443] Step 3: Synthesis of 2-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)ethyl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-valine

[0444] Compound 93 (70 mg, 0.159 mmol) and HATU (74 mg, 0.195 mmol) were added to N, N-dimethylformamide (5 mL), stirred at room temperature for 10 minutes, and then compound 94 (84 mg, 0.158 mmol) and DIEA (200 uL, 1.209 mmol) were added and stirred at room temperature for 4 hours. LCMS showed that there was a small amount of compound 94 remaining in the reaction solution, and the reaction was completed. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation using acetonitrile / water. Compound 95 (solid oil, 140 mg, yield 102.5%) was obtained. MS: 859.92 [M+H] +.

[0445] Step 4: Synthesis of 2-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)ethyl L-valine

[0446] Compound 95 (140 mg, 0.163 mmol) was placed in a 25 mL single-mouth bottle, and N,N-dimethylformamide (3 mL) and DEA (0.5 ml) were added. The reaction was carried out at room temperature for 20 min, and LCMS monitored the complete reaction of the raw material compound 95. After being spin-dried, the crude product was purified by preparative liquid phase separation to obtain compound 96 (white solid, 86 mg, yield 82.9%) MS: 637.68 [M+H] +.

[0447] Step 5: 2-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-oxoethoxy)ethyl(2S,5S)-5-(3-(tert-butyloxy)-3-oxopropyl)- Synthesis of 41-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-2-isopropyl-9-(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-4,7,11,39-tetraoxo-14,17,20,23,26,29,32,32,35-octaoxo-3,6,10,38-tetra-tetraoctanoic acid azaphenyl ester

[0448] Compound 65 (23 mg, 0.021 mmol) and HATU (11 mg, 0.029 mmol) were added to N,N-dimethylformamide (3 mL), stirred at room temperature for 10 minutes, and then compound 96 (15 mg, 0.023 mmol) and DIEA (15 uL, 0.093 mmol) were added and stirred at room temperature for 4 hours. The reaction was considered to be complete when LCMS showed that the reaction solution contained less than 3% of compound 96. The reaction solution was evaporated to dryness under reduced pressure, and the crude product was purified by preparative liquid separation. Compound 97 (white solid, 16 mg, yield 44.7%) was obtained. MS: 852.42 [M+2H] 2+ / 2.

[0449] Step 6: (37S)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-37-((S)-1-)2-(2-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-1 Synthesis of [(2-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxoethyl)-3,31,35-trioxo-7,10,13,16,19,22,25,28-octaoxa-4,32,36-triazatetracarbonane-40-carboxylic acid]]

[0450] Compound 97 (16 mg, 0.0094 mmol) was placed in a 25 mL single-mouth bottle, and dichloromethane (2.5 mL) and trifluoroacetic acid (2.5 ml) were added. The reaction was allowed to react at room temperature for 1 h. LCMS monitored that the reaction of the raw material compound 97 was complete. The reaction solution was evaporated under reduced pressure to dry the solvent, and the crude product was separated and purified by HPLC. The solvent was freeze-dried to obtain compound DL-21 (white solid, 5 mg, yield 32.3%). MS: 824.37 [M+2H] 2+ / 2

[0451] 1 H NMR (400MHz, DMSO-d6) δ8.41(d,J=8.8Hz,1H),8.13–8.03(m,1H),8.02–7.96(m,1H),7.87(m,1H),7.82–7.75(m,1H),7.31(s,1H) ),6.99(s,1H),6.51(s,1H),5.42(s,1H),5.21(s,1H),4.89(s,1H),4.70(s,1H),4.46(m,2H),4.40–4.22(m,5H),4.16(m,1H),4. 06(m,2H),3.73(m,3H),3.63–3.43(m,35H),3.36(m,5H),3.17(m,4H),2.99(m,2H),2.80(d,J=2.5Hz,2H),2.40(s,3H),2.36–2.2 9(m,3H),2.30–2.14(m,6H),1.99–1.91(m,1H),1.85(m,3H),1.74–1.62(m,1H),0.91–0.82(m,4H),0.78(dd,J=11.5,6.8Hz,5H).

[0452] Preparation example:

[0453] General Procedure Antibody Reduction:

[0454] To the PBS buffer solution of trastuzumab (0.05M PBS aqueous solution at pH = 7.0; 2 mg, 0.014 μmol), add the prepared reducing agent tri(2-carboxyethyl)phosphine aqueous solution (4-10 eq), protect with inert gas, place in a water bath or metal bath, shake and react at 25-37° C. for 0.5-2.0 hours, stop the reaction, and cool the reaction solution to room temperature for subsequent coupling reaction.

[0455] ADC synthesis:

[0456]

[0457] The aqueous solution of compound DL-1 (0.388mL, 1mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.0 hour, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution of pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-1 (5.8mg / mL, 0.33mL), which was stored frozen at -80°C. The average DAR value was calculated by reduction-reverse phase chromatography method, and the value was n=5.4.

[0458]

[0459] The aqueous solution of compound DL-2 (0.096mL, 4mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.0 hour, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-2 (11.9mg / mL, 0.15mL), which was stored frozen at -80°C. The average DAR value was calculated by reduction-reverse phase chromatography method, and the value was n=7.7.

[0460]

[0461] The aqueous solution of compound DL-3 (0.126mL, 3mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.0 hour, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-3 (12.4mg / mL, 0.15mL), which was stored frozen at -80°C. The DAR value calculated by the reduction-reverse phase chromatography method was approximately n=6.5.

[0462]

[0463] The aqueous solution of compound DL-4 (0.126mL, 3.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a shaker, shaken at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a shaker, shaken at room temperature for 1.0 hour, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-4 (6.5mg / mL, 0.2mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately n=7.0.

[0464]

[0465] The aqueous solution of compound DL-5 (0.188mL, 2.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, placed in an oscillating mixer under inert gas protection, and oscillated at room temperature for 1.5 hours to stop the reaction. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, placed in an oscillating mixer under inert gas protection, and oscillated at room temperature for 1.0 hour to stop the reaction. The reaction solution was ultrafiltered using an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-5 (4.6mg / mL, 0.3mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately n=4.2.

[0466]

[0467] The aqueous solution of compound DL-6 (0.382mL, 1.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.0 hour, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-6 (5.9mg / mL, 0.33mL), which was stored frozen at -80°C. The DAR value calculated by the reduction-reverse phase chromatography method was approximately n=5.8.

[0468]

[0469] The aqueous solution of compound DL-7 (0.098mL, 4.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a shaker, shaken at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a shaker, shaken at room temperature for 1.0 hour, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-7 (7.9mg / mL, 0.23mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately n=7.1.

[0470]

[0471] The aqueous solution of compound DL-8 (0.110mL, 3.5mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a shaker, shaken at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a shaker, shaken at room temperature for 1.0 hour, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-8 (8.2mg / mL, 0.25mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately n=7.3.

[0472]

[0473] The aqueous solution of compound DL-9 (0.092mL, 4.1mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, placed in an oscillating mixer under inert gas protection, and oscillated at room temperature for 1.5 hours to stop the reaction. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, placed in an oscillating mixer under inert gas protection, and oscillated at room temperature for 0.3 hours to stop the reaction. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-9 (4.96mg / mL, 0.36mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately n=7.1.

[0474]

[0475] The aqueous solution of compound DL-10 (0.098mL, 4.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, placed in an oscillating mixer under inert gas protection, and oscillated at room temperature for 1.5 hours to stop the reaction. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, placed in an oscillating mixer under inert gas protection, and oscillated at room temperature for 0.3 hours to stop the reaction. The reaction solution was ultrafiltered using an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-10 (5.88mg / mL, 0.35mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately n=6.5.

[0476]

[0477] The aqueous solution of compound DL-11 (0.096mL, 4.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 0.3 hours, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-11 (7.72mg / mL, 0.24mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately n=5.3.

[0478]

[0479] The aqueous solution of compound DL-12 (0.097mL, 4.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, placed in an oscillating mixer under inert gas protection, and oscillated at room temperature for 1.5 hours to stop the reaction. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, placed in an oscillating mixer under inert gas protection, and oscillated at room temperature for 0.3 hours to stop the reaction. The reaction solution was ultrafiltered using an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-12 (6.12mg / mL, 0.305mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately n=5.0.

[0480]

[0481] The aqueous solution of compound DL-13 (0.096mL, 4.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 0.3 hours, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-13 (5.68mg / mL, 0.32mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately n=4.2.

[0482]

[0483] The aqueous solution of compound DL-14 (0.100mL, 4.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a shaker, and oscillated at room temperature for 1.5 hours to stop the reaction. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a shaker, and oscillated at room temperature for 0.3 hours to stop the reaction. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-14 (4.72mg / mL, 0.33mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately n=5.6.

[0484]

[0485] The aqueous solution of compound DL-15 (0.096mL, 4.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 0.3 hours, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-15 (5.31mg / mL, 0.32mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately n=7.4.

[0486]

[0487] The aqueous solution of compound DL-17 (0.096mL, 4.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a shaker, and oscillated at room temperature for 1.5 hours to stop the reaction. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a shaker, and oscillated at room temperature for 0.3 hours to stop the reaction. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH = 7.0 to obtain a PBS buffer solution of the coupling product ADC-16 (6.19mg / mL, 0.3mL), which was stored frozen at -80°C. The DAR value calculated by reduction-reverse phase chromatography was approximately n = 4.5.

[0488]

[0489] The aqueous solution of compound DL-18 (0.091mL, 3.5mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.0 hour, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-16 (11.2mg / mL, 0.15mL), which was stored frozen at -80°C. The DAR value calculated by the reduction-reverse phase chromatography method was approximately the average DAR value calculated to be n=7.45.

[0490]

[0491] The aqueous solution of compound DL-19 (0.157mL, 2.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a oscillating mixer, oscillated at room temperature for 1.0 hour, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-17 (5.2mg / mL, 0.3mL), which was stored frozen at -80°C. The DAR value calculated by the reduction-reverse phase chromatography method is approximately the average DAR value calculated to be n=6.9.

[0492]

[0493]

[0494] The aqueous solution of compound DL-20 (0.317mL, 1.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a shaker, shaken at room temperature for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, inert gas protection, placed in a shaker, shaken at room temperature for 1.0 hour, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-19 (8.5mg / mL, 0.2mL), which was stored frozen at -80°C. The DAR value calculated by the reduction-reverse phase chromatography method is approximately the average DAR value calculated to be n=7.3.

[0495]

[0496] The aqueous solution of compound DL-21 (0.082mL, 4.0mg / mL, 0.2μmol) was added to the above 0.208mL antibody reaction solution, inert gas protection, placed in a shaker, oscillated at 25°C for 1.5 hours, and the reaction was stopped. The aqueous solution of compound NAC (0.004mL, 100mM, 0.4μmol) was added to the reaction solution, filled with Ar gas, placed in a shaker, oscillated at 25°C for 0.3 hours, and the reaction was stopped. The reaction solution was ultrafiltered with an Amicon Ultra-15 30kD ultrafiltration tube at a speed of 12000rpm at 10°C using a 0.05M PBS buffer solution with pH=7.0 to obtain a PBS buffer solution of the coupling product ADC-20 (5.1mg / mL, 0.32mL), which was stored frozen at -80°C. The DAR value calculated by the reduction-reverse phase chromatography method is approximately the average DAR value calculated to be n=7.1.

[0497] Among them, the ADC sample analysis and detection method is as follows:

[0498] 1.HIC detection

[0499] Prepare a solution of 25mM phosphate buffer and 1.2M ammonium sulfate, take an appropriate amount of sample, add solvent to dissolve and dilute in a ratio of 1:1. Use butyl-bonded polymethacrylic acid matrix as filler (TOSOH TSKgel Butyl-NPR 2.5μm 4.6*35mm or chromatographic column with equivalent performance); use 25mM phosphate buffer and 1.2M ammonium sulfate solution as mobile phase A; 25mM phosphate buffer-isopropanol (80-20) as mobile phase B; elute with mobile phase gradient (B: 0-100%); detection wavelength is 280nm; column temperature is room temperature; flow rate is 0.5ml per minute; injection volume is 50μl.

[0500] 2.SEC detection

[0501] Take an appropriate amount of this product, add solvent to dissolve and dilute it to make about 1-2 mg of sample per 1 ml, use diol-bonded gel as filler (Waters Xbridge Premier Protein SEC 7.8*300mm or chromatographic column with equivalent performance); use 20mM phosphate buffer and 150mM sodium chloride solution as mobile phase; detection wavelength is 280nm; column temperature is room temperature; flow rate is 0.8ml per minute; injection volume is 10μl.

[0502] 3. Reverse phase detection

[0503] Prepare mobile phase A: 0.5‰ TFA acetonitrile solution, mobile phase B: 0.5‰ TFA aqueous solution. Take 20μL of the sample to be tested (1mg / mL), add 1μL of DTT (10mM), and react at room temperature for 30min for reduction. Use chromatographic column: Aglient PLRP-S1000A 5μm, 50*2.1mm, and perform gradient elution at 70℃ (mobile phase A: 0-100%).

[0504] Test Example 1: In vitro proliferation inhibition test of ADC drugs on tumor cells

[0505] 1. Purpose of the experiment

[0506] The purpose of this experiment is to detect the in vitro proliferation inhibitory activity of the ADC drug of the present invention on tumor cells with different expression levels. The proliferation inhibitory activity of tumor cells NCI-N87 cells, SK-BR-3 cells, JIMT-1 cells, and MCF7 cells was detected respectively. After the cells were treated with different concentrations of ADC drugs in vitro and cultured for 6 days, the cell viability was detected using CTG (CellTiter-Glo Luminescent Cell Viability Assay, Promega, Catalog No. G7571) reagent, and the proliferation inhibitory effect of ADC drugs on tumor cells was evaluated according to IC50.

[0507] 2. Experimental methods

[0508] 1) Cell culture

[0509] NCI-N87 cells (Cell Bank of the Chinese Academy of Sciences, Catalog No. TCHu130) and SK-BR-3 cells (Cell Bank of the Chinese Academy of Sciences, Catalog No. TCHu225) were cultured with 1640 complete medium containing 15% FBS and McCoy's5A complete medium containing 10% FBS, respectively. JIMT-1 cells (Nanjing Kebai Biological, CBP60378) and MCF7 cells (Cell Bank of the Chinese Academy of Sciences, Catalog No. TCHu74) were cultured with DMEM complete medium containing 10% FBS.

[0510] 2) Cell preparation

[0511] Take the stable cells, wash them twice with 5-10mL DPBS, and then add 1-2mL of 0.25% Trypsin-EDTA for digestion. After the cells are completely digested, add 2.5-3 times the volume of trypsin in the culture flask to stop the digestion. Transfer the digested cells to a centrifuge tube and centrifuge at 1000rpm for 5min. After centrifugation, discard the supernatant, add complete medium to resuspend, and gently blow evenly before counting the cells.

[0512] 3)Planning

[0513] NCI-N87 cells were diluted to 5.55×104 cells / mL using complete medium, and 90 μL was added to each well of a 96-well white opaque plate at a predetermined position. At the same time, the edge wells were filled with sterile DPBS at a filling volume of 200 μL / well and placed in a 37°C, 5% CO2 incubator for overnight culture to adhere to the plate;

[0514] 4) Sample preparation

[0515] Pre-dilute the ADC samples to 1350nM with complete medium. Then dilute them 5-fold with complete medium, for a total of 9 gradients. Add the diluted ADC samples to the predetermined positions of the 96-well plate at 10μL / well, with 2 replicates for each concentration. Add complete medium to the cultured cells in the 11th column as a control for normal cell growth.

[0516] 5) Cultivation

[0517] After adding, tap the plate several times around the sides to mix the sample and culture medium evenly, and then place the plate in a 37°C, 5% CO2 cell culture incubator for 6 days.

[0518] 6) Cell viability assay

[0519] After 6 days of culture, After the reagents were thawed and the cell culture plates were placed at room temperature for 30 minutes, 50 μL was added to each well. The cell plates were shaken and lysed on an oscillator for 2 minutes and then incubated at room temperature for 10 minutes to stabilize the luminescent signal.

[0520] 7) Plate reading

[0521] The luminescence chemiluminescence value was read by BMG Omega microplate reader, and the results are shown in Table 1 below.

[0522] 3. Experimental results

[0523] Table 1

[0524]

[0525]

[0526] It can be seen that the ADC drugs of the present invention have obvious proliferation inhibitory activity on four tumor cells, NCI-N87, SK-BR-3, JIMT-1 and MCF7, and the inhibitory effect of some ADC drugs is greater than that of the positive control DS8201, especially in inhibiting the proliferation of JIMT-1 and MCF7 breast cancer tumor cells.

[0527] Test Example 2: Evaluation of the efficacy of ADC drugs on JIMT-1 tumor-bearing mice

[0528] 1. Purpose of the experiment

[0529] The anti-tumor effect of the ADC drug of the present invention was evaluated in a female NOD / SCID mouse animal model with subcutaneous xenografts of human breast cancer JIMT-1 cell line.

[0530] 2. Experimental methods

[0531] NOD / SCID mice were subcutaneously inoculated with human JIMT-1 breast cancer tumor cells to establish a subcutaneous transplantation model of human breast cancer. The experiment was divided into a solvent control group, an ADC-2 (MPA-4) 3mg / kg test drug group, an ADC-16 (MPD-4) 3mg / kg test drug group, and a DS8201 3mg / kg test drug group, a total of 4 groups, 6 mice in each group, and intravenous injection was given once on the day of grouping. The efficacy was evaluated based on the relative tumor inhibition rate (TGI), and the safety was evaluated based on the changes in animal weight and death.

[0532] After tumor cell inoculation, routine monitoring includes tumor growth and the effect of treatment on the normal behavior of animals, including the activity of experimental animals, food and water intake, weight gain or loss, eyes, fur and other abnormalities. Clinical symptoms observed during the experiment are recorded in the original data. After the start of drug administration, the weight and tumor size of mice are measured twice a week. Tumor volume calculation formula: Tumor volume (mm 3 )=1 / 2×(a×b 2 ) (where a represents the long diameter and b represents the short diameter). StudyDirectorTM (version 3.1.399.19, supplier Studylog System, Inc.) software was used to collect data in the experiment, including the measurement of the long and short diameters of the tumor and the weighing of the animal body weight. The original data was directly imported into the software after being measured by a balance and a vernier caliper, and any changes in the data will be recorded in this software. The entire process of drug administration, tumor measurement, and body weight weighing was carried out in a biological safety cabinet or ultra-clean workbench.

[0533] Tumor proliferation rate (T / C (%)): T / C = TmTV / CmTV × 100%; TmTV: average of the treatment group; CmTV: average of the control group; Tumor inhibition rate (TGI (%)): TGI = (1-T / C) × 100%; where T / C% is the tumor proliferation rate, which is the percentage value of the relative tumor volume (or body weight) of the treatment group and the control group at a certain time point.

[0534] 3. Experimental results

[0535] like Figure 1 As shown, the average tumor volume of mice in the vehicle control group was 906.20 mm on day 28. 3 The average tumor volume of the ADC-2 (MPA-4) 3 mg / kg test drug group on day 28 was 15.87 mm 3 The relative tumor inhibition rate TGI (%) was 98.29%, which was statistically significantly different from the control group (p<0.001), and the tumor complete inhibition rate was 3 / 6. The average tumor volume of the ADC-16 (MPD-4) 3mg / kg test drug group on day 28 was 423.93mm 3 The relative tumor inhibition rate TGI (%) was 52.91%, which was statistically significant compared with the control group (p<0.001). The average tumor volume of the DS8201 3mg / kg test drug group on day 28 was 893.02mm 3 The relative tumor inhibition rate TGI (%) was 9.31%, which had no statistically significant difference compared with the control group (p>0.05).

[0536] The ADC-2 (MPA-4) 3mg / kg, ADC-16 (MPD-4) 3mg / kg and DS8201 3mg / kg test drug groups did not cause weight loss in mice ( Figure 2 ), and no animal died in each treatment group, and the treatment was well tolerated.

Claims

1. A compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, PLD(I) in, P has the following structure: m and n are each independently selected from any integer from 0 to 12; X1 is selected from a bond, a C1-C6 alkylene group, an imino group, an ester group, an amide group, a carbonate group, a carbamate group, a sulfone group, a sulfonamide group, a ketone group, a urea group or a phosphate group; X2 is selected from a bond, nitrogen, oxygen, sulfur, phosphorus, a C1-C6 alkylene group, an imino group, an ester group, an amide group, a carbonate group, a carbamate group, a sulfone group, a sulfonamide group, a ketone group, a urea group or a phosphate group; L has the following structure: n1 and n2 are each independently selected from any integer from 0 to 6; R1 is selected from a hydrophilic group; R2 and R3 are each independently selected from H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, or R2 and R3 together with the carbon atoms to which they are attached form a C3-C6 cycloalkyl, wherein one or more hydrogen atoms in the C1-C6 alkyl, C1-C6 haloalkyl or C3-C6 cycloalkyl are optionally substituted with halogen, hydroxyl, cyano, amino, C1-C3 alkyl or phenyl; R4 is selected from the R group in the α-amino acid general formula R-CH(NH2)COOH; R5 is selected from a bond or -Y1-R6-Y2-, wherein Y1 is a bond, -NH- or -O-, Y2 is -NH- or -C=O-, and R6 is selected from -(CH2) z -、-(OCH2) z -、-(CH2O) z -、-(CH2CH2O) z -、-(OCH2CH2) z -, C3-C6 cycloalkyl or a covalently linked combination thereof, z is selected from any integer from 0 to 6; and D is a toxin molecule or other equivalent.

2. The compound of formula (I) according to claim 1, wherein the hydrophilic group has at least three ether bonds and / or hydroxyl groups consisting of oxygen-containing groups, preferably, the hydrophilic group has any one of the following structures:

3. formula (I) compound according to claim 1, wherein R2 and R3 are each independently selected from H, F, Cl, methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or R2 and R3 form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl together with the carbon atom to which they are connected, wherein one or more hydrogen atoms in said methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl are optionally replaced by halogen, hydroxyl, cyano, amino, C1-C3 alkyl or phenyl.

4. The compound of formula (I) according to claim 1, wherein R4 is selected from the R group of glutamic acid, aspartic acid, lysine, arginine, histidine, alanine, valine or tryptophan; preferably glutamic acid, aspartic acid or lysine.

5. The compound of formula (I) according to claim 1, wherein R5 is selected from a bond, -O-(CH2) z -NH-, -(OCH2) z -NH-, -(OCH2) z -CO-, -(OCH2CH2) z -CO- or -(OCH2CH2) z -NH-, z is selected from any integer from 1 to 3; preferably a bond, -(OCH2) z -CO-, -(OCH2CH2) z -CO- or -(OCH2CH2) z -NH-.

6. The compound of formula (I) according to claim 1, wherein the toxin molecule is a microtubule disruptor, an anti-mitotic inhibitor or a DNA damaging drug.

7. The compound of formula (I) according to claim 1, wherein the toxin molecule is a maytansine, auristatin, paclitaxel, anthramycin, calicheamicin, duocarmycin, camptothecin or amanitin toxin molecule.

8. The compound of formula (I) according to claim 1, wherein the toxin molecule is an auristatin F derivative having the following structure:

9. The compound of formula (I) according to claim 1, wherein the toxin molecule is an exitecan analogue having the following structure:

10. A conjugate comprising a compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof as a conjugation precursor of the conjugate according to any one of claims 1 to 9. The conjugate according to claim 10 , wherein the conjugate further comprises a targeting moiety.

12. The conjugate according to claim 11, wherein the targeting moiety forms a free thiol group by reduction of the interchain disulfide bond for coupling with the maleimide group of the compound of formula (I).

13. The conjugate according to claim 11, wherein the DAR value is any integer or decimal between 1 and 10, preferably between 4 and 8.

14. The conjugate according to claim 10, wherein the targeting moiety is selected from antibodies, synthetic functionalized antibodies, peptides or other targeting ligands.

15. The conjugate of claim 14, wherein the targeting moiety is an antibody or a synthetic functionalized antibody specific for an antigen overexpressed in cancer cells.

16. The conjugate of claim 15, wherein the targeting moiety is an antibody or synthetic functionalized antibody specific for an antigen selected from the group consisting of HER2, EGFR, Claudin18.2, c-MET, Nectin-4, ROR1, GPNMB, CD56, TACSTD2 (TROP2), CEACAM5, folate receptor-a, mesothelin, ENPP3, guanylate cyclase C, SLC44A4, NaPi2b, CD70, mucin 1, STEAP1, connexin 4, 5T4, SLTRK6, SC-16, LIV-1, P-cadherin, PSMA, fibronectin extracellular domain B, endothelin receptor ETB, tenascin c, collagen IV, VEGFR2, periostin, CD30, CD79b, CD19, CD22, CD138, CD37, CD33, CD74, CD19 and CD98.

17. The conjugate of claim 16, wherein the targeting moiety is trastuzumab or synthetically functionalized trastuzumab.

18. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 9 or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof, or a conjugate according to any one of claims 10 to 17; and a pharmaceutically acceptable carrier.

19. The pharmaceutical composition according to claim 18, wherein the dosage form is selected from tablets, capsules, granules, powders, syrups, inhalants or injections.

20. Use of a compound of formula (I) or an isotope-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or isomer mixture thereof, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, or a conjugate according to any one of claims 10 to 17 in the preparation of a medicament for treating or preventing cancer in a subject in need thereof.

21. The use according to claim 20, wherein the cancer is a HER2 positive cancer.

22. The use according to claim 21, wherein the HER2-positive cancer is a cancer in which HER2 is overexpressed.

23. The use according to claim 22, wherein the cancer is breast cancer.

24. The use according to claim 20, wherein the drug is an antibody-drug conjugate.